



HAL
open science

Novel thienopyrimidones targeting hepatic and erythrocytic stages of Plasmodium parasites with increased microsomal stability

Prisca Lagardère, Romain Mustière, Nadia Amanzougaghene, Sébastien Hutter, Marion Casanova, Jean-François Franetich, Shahin Tajeri, Aurélie Malzert-Fréon, Sophie Corvaisier, Marc Since, et al.

► To cite this version:

Prisca Lagardère, Romain Mustière, Nadia Amanzougaghene, Sébastien Hutter, Marion Casanova, et al.. Novel thienopyrimidones targeting hepatic and erythrocytic stages of Plasmodium parasites with increased microsomal stability. *European Journal of Medicinal Chemistry*, 2023, 261, pp.115873. 10.1016/j.ejmech.2023.115873 . hal-04503282

HAL Id: hal-04503282

<https://amu.hal.science/hal-04503282>

Submitted on 13 Mar 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Novel Thienopyrimidones Targeting Hepatic and Erythrocytic Stages of *Plasmodium* Parasites with Increased Microsomal Stability.

Prisca Lagardère,^a Romain Mustière,^b Nadia Amanzougaghene,^c Sébastien Hutter,^d Marion Casanova,^d Jean-François Franetich,^c Shahin Tajeri,^c Aurélie Malzert-Fréon,^e Sophie Corvaisier,^e Marc Since,^e Nadine Azas,^d Patrice Vanelle,^{b, f} Pierre Verhaeghe,^{g, h, i} Nicolas Primas,^{b, f} Dominique Mazier,^c Nicolas Masurier^{a*} and Vincent Lisowski^{a*}

- a. Institut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, ENSCM, UFR des Sciences Pharmaceutiques et Biologiques, Montpellier, France.
- b. Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, 13385 Marseille cedex 05, France.
- c. Centre d'Immunologie et des Maladies Infectieuses (CIMI), INSERM, CNRS, Sorbonne Université, Paris, France.
- d. Aix Marseille Université, IRD, AP-HM, SSA, VITROME, Marseille, France.
- e. CERMN, Université de Caen Normandie, UNICAEN.
- f. AP-HM, Hôpital Conception, Service Central de la Qualité et de l'Information Pharmaceutiques, 13005 Marseille, France.
- g. Univ. Grenoble Alpes, CNRS, DPM UMR 5063, F-38041, Grenoble, France
- h. LCC-CNRS Université de Toulouse, CNRS, UPS, Toulouse, France
- i. CHU de Nîmes, Service de Pharmacie, Nîmes, France

*Correspondence: nicolas.masurier@umontpellier.fr; Tel.: +33-4117-59642;
vincent.lisowski@umontpellier.fr; Tel.: +33-411 7-59599

Abstract

Based on the structure of a previously identified hit, Gamhepathiopine **1**, which showed promising antiplasmodial activity, but poor microsomal stability, several strategies were investigated to improve the metabolic stability of the compounds. This included the introduction of fluorine or deuterium atoms, as well as carbocyclic groups. Among the new compounds, the 2-aminocyclobutyl derivative **5g** demonstrated enhanced microsomal stability compared to compound **1**, while retaining antiplasmodial activity against erythrocytic and hepatic stages of *Plasmodium*, without significant cytotoxicity against primary hepatocytes.

37

1. Introduction

38

39

40

41

42

43

44

45

46

47

48

49

50

Malaria is a potentially life-threatening disease caused by the *Plasmodium* parasite, which is transmitted to humans through the bites of infected *Anopheles* mosquitoes. Among the species that can infect humans, *Plasmodium falciparum* is responsible for the majority of malaria cases and deaths, especially in sub-Saharan Africa. In 2021, an estimated 247 million cases of malaria and 619,000 deaths occurred worldwide, with the highest burden in children under the age of five.[1] Over the past 20 years, tremendous progress has been made in the diagnosis (rapid diagnostic test (RDT), microscopy-based analysis, thick and thin layer blood smear analysis...),[2] prevention (vector control,[3] vaccines[4]) and effective treatment of malaria.[5] However, despite the availability of several effective drugs for malaria treatment, the emergence and spread of drug-resistant strains of the parasite,[6,7] as well as the high cost, limited efficacy, and potential side effects of some existing drugs, highlight the need for the discovery and development of new antimalarial compounds, particularly those active against multiple stages of parasite development.

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66


67

68

69

In this context, Gamhepathiopine (Fig. 1) has been identified as a hit compound, with potent antiplasmodial activity against both the sexual and asexual stages of *Plasmodium falciparum*. [8,9] However, the evaluation of the *in vivo* activity of this compound is limited by its low aqueous solubility and high metabolism by cytochromes P450. In order to improve these parameters, while maintaining or enhancing its antiplasmodial activity, extensive structure-activity relationship (SAR) studies have been carried out, based on the structure of Gamhepathiopine **1** [9–14]. Previous studies have shown a preference for a *p*-tolyl group at R₁ and a hydrogen at position 7 (Figure 1).[9] Some improvements in the antiplasmodial activity against the hepatic stage of *P. berghei* were achieved by introducing aminoalkyl chains at position 4 of the thienopyrimidine core. Additionally, the introduction of diamines at this position increased the hydrosolubility and the microsomal stability of the compounds. [10,14] However, it was observed that this led to increased cytotoxicity against mammalian cells, resulting in a low selectivity index. This strategy has therefore not been explored further, and a carbonyl group at position 4 appears to be the best compromise between antiplasmodial activity and safety. In position 2, short and bulky aminoalkyl moieties are needed, while long aminoalkyl chains decrease activity and aqueous solubility. To complete the SAR and enhance the microsomal stability of this series of compounds, we present the synthesis and biological activity of new 2-aminosubstituted thienopyrimidone derivatives. Specifically, the introduction of cyclic amines, fluoroalkyl chains and ionizable functions were studied. We also

70 considered the modulation of position 3 of the pyrimidine moiety with alkyl or aryl groups
71 (Figure 1).



72


73 **Figure 1.** Gamhepathiopine structure and previous SAR studies.

74 2. Results and Discussion

75 2.1. Chemistry


76 All 2-aminosubstituted derivatives were prepared according to Scheme 1. Methyl 3-amino-5-
77 (*p*-tolyl)thiophene-2-carboxylate **2**[9] reacted with ethoxycarbonyl isothiocyanate in
78 dimethylformamide (DMF) to yield intermediate **3**. The latter reacted with a set of primary and
79 secondary amines in presence of EDCI and triethylamine to afford the corresponding guanidine
80 derivatives **4**. The targeted compounds **5a-p** were obtained through final cyclization at 170°C
81 and subsequently purified by chromatography, with yields ranging from 35% to 79%. For
82 compounds containing an additional nitrogen (azetidine or pyrrolidine moiety),
83 thienopyrimidones **5o** and **5p**, protected by a Boc group, were synthesized. Final acidic
84 deprotection led to compounds **6a-b**, isolated as their corresponding hydrochloric salts. The
85 structures of all final compounds were confirmed with different spectral analyses, such as ¹H-
86 NMR, ¹³C-NMR, mass spectroscopy and high-resolution mass spectrometry. It should be noted
87 that in the case of the insertion of a 3-aminopropyl dimethylamine (compound **5e**) or a 3-
88 aminoazetidine (compound **6a**), the ¹H NMR spectrum of these two compounds suggested the
89 presence of an exocyclic double bond. Indeed, the signal around 10 ppm, which is attributed
90 to the NH in position 3, and which is present in the spectra of all other analogues has
91 disappeared. Furthermore, the presence of a triplet at 3.95 ppm for compound **5e** and a
92 quintuplet at 4.95 ppm for compound **6a** was observed; these signals were attributed to the
93 methylene in the alpha position of the guanidine function, suggesting the absence of a
94 neighbouring NH in these two compounds. In contrast, for all other compounds, this

95 methylene consistently displayed a multiplicity compatible with the presence of an exocyclic
 96 NH.



Scheme 1. Synthesis of 2-amino-substituted thienopyrimidones **5** and **6**. Reagents and conditions: (i) SCNCO₂Et, DMF, 30°C, 2 h; (ii) R₂NH₂, NEt₃, EDCI.HCl, DMF, RT, 18 h; (iii) 170°C and 2 h; (iv) 1,4-dioxane/HCl 37% 4:1 v:v, RT.

Then, we turned our attention to the preparation of 3-substituted derivatives (Scheme 2). Initially, the direct alkylation of gamhepathiopine **1** was studied, using 1.1 equivalents of sodium hydride and benzyl bromide as alkylating agent, in dry THF. Under these conditions, only traces of several mono-benzylated compounds were detected by LC-MS analysis, even after 6 days of reaction. Due to the low reactivity of the starting material and the lack of selectivity in alkylation, an alternative approach using an aza-Wittig reaction was explored, starting from compound **2**. Thus, the reaction between triphenylphosphine and **2** in the presence of hexachloroethane in dry acetonitrile at 0°C afforded the corresponding iminophosphorane **7** in 65% yield, after recrystallization in ethanol. Carbodiimides **8** were then prepared by reacting compound **7** with three different isocyanates in dichloromethane at room temperature. An aryl (phenyl), a linear (ethyl) and a ramified alkyl (isopropyl) isocyanate were chosen to introduce diversity at position 3 of the final thienopyrimidones **10a-c**. Depending on the nature of the isocyanate substituent, adjustments to the operating conditions were applied. Phenylisocyanate reacted smoothly at 0°C, resulting in complete conversion of **7** after 15 hours (followed by HPLC), whereas ethyl- and isopropylisocyanate proved to be less reactive under these conditions. With ethylisocyanate, total conversion was achieved after 48 hours at 35°C, while the isopropyl derivative required 48 hours at 65°C. Carbodiimides **8a-c** were not isolated and reacted directly with *tert*-butylamine to generate substituted guanidine derivatives **9a-c**. The latter were cyclized in the presence of sodium ethylate in ethanol to afford the corresponding 3-substituted thienopyrimidones **10a-c** in 3-step overall yields of 45% to 59%, after recrystallization.



122

123 **Scheme 2.** Synthesis of 3-substituted thienopyrimidones **10**. Reagents and conditions: (i) PPh₃, C₂Cl₆, dry
 124 ACN, 0°C, and 2 h 30; (ii) R₂NCO, DCM, 0°C, 15 h for **8a**, DCM, 35°C, 48h for **8b**, THF, reflux, and 48 h for
 125 **8c**; (iii) *t*BuNH₂, DCM, RT; (iv) EtONa, EtOH, RT.

126

127 2.2. Biological evaluation

128 2.2.1. Blood-stage Antiplasmodial Activity and Cytotoxic Activity against HepG2 Human Cells

129 All newly synthesized 2-aminosubstituted and 3-substituted thieno[3,2-*d*]pyrimidines were
 130 screened for their activity against asexual erythrocytic stage parasites of a multidrug-resistant
 131 *P. falciparum* K1 strain (In order to investigate the impact of the substitution of position 3 in
 132 this series of compounds, compounds **10a-c** were evaluated on the erythrocytic stage of *P.*
 133 *falciparum*. Compounds **10a** and **10b** were inactive (EC₅₀ > 12.5 μM). On the other hand, **10c**
 134 showed very low activity on *P. falciparum* compared to Gamhepathiopine **1** (EC₅₀ of 4.2 μM vs.
 135 0.2 μM). Furthermore, this substitution led to an increase in the cytotoxicity of the compounds,
 136 particularly for compound **10b**, which exhibited a CC₅₀ value of 6.3 μM against the HepG2 cell
 137 line. Hence, the presence of an NH group at position 3 appears to be essential for the
 138 antiplasmodial activity of this series of compounds and was consistently maintained in all other
 139 synthesized derivatives.

140 Then, we focused on the influence of modulating position 2 of the thienopyrimidone scaffold.
 141 Initially, the introduction of a methylamine group in position 2 was considered in view of the
 142 activity of different series of thieno[3,2-*d*]pyrimidine analogues proposed by González Cabrera
 143 *et al.*, which showed strong activity on several strains of *P. falciparum*. [15,16] However, in our
 144 hands, the 2-aminomethyl analogue **5a** was found to be inactive. This result demonstrates
 145 that, despite the structural similarity with other reported antiplasmodial compounds,
 146 Gamhepathiopine derivatives do not appear to share the same mechanism of action.

147 Then, as gamhepathiopine **1** was highly metabolized in the presence of female mouse
148 microsomes (half-life, $t_{1/2}$ = 11 min) and the *tert*-butyl group at position 2 proved to be highly
149 sensitive to oxidation, the introduction of more stable groups was considered in order to
150 decrease metabolism at this position. In drug design, a common strategy involves replacing
151 chemical groups that are substrates of cytochromes with bioisosteres called metabolic
152 blockers, such as fluorine or deuterium atoms. Deuterium, a heavy and non-radioactive
153 isotope of hydrogen, has been officially recognized in medicinal chemistry since 2017,
154 following the FDA approval of the first deuterated drug (Deutetrabenazine), for the treatment
155 of Huntington's disease. [17] Deuterium is mainly used for its kinetic isotope effect. It
156 expresses twice the mass of hydrogen; therefore, the carbon-deuterium bond is more stable
157 and resistant to oxidative processes that may occur during phase I reactions of metabolism.
158 Additionally, deuterium exhibits steric and electronic properties similar to hydrogen.[18] This
159 alternative isostere effectively limits oxidation and improves the pharmacokinetic properties
160 of compounds, such as their half-life and clearance. On the other hand, the introduction of a
161 fluorine atom or fluorinated groups is a widely employed approach to address metabolic
162 stability liabilities. Fluorine possesses a Van der Waals radius similar close to hydrogen (1.47 Å
163 vs. 1.20 Å), and the strength of the carbon-fluorine bond exceeds that of the carbon-hydrogen
164 bond.[19] Consequently, phase I oxidation reactions are more difficult, without significantly
165 altering the structure of the compound. Therefore, to enhance the metabolic stability of
166 gamhepathiopine, introduction of a fluorine or deuterium atom(s) at position 2 was
167 considered. Thus, the deuterated analogues (**5b** and **5c**), respective bioisosteres of compounds
168 **11**[9] and **1**, as well as the fluorinated derivative **5d** were synthesized and evaluated. While
169 the monotrifluoromethyl analogue of **1** was inactive (compound **5d**), the deuterated
170 compounds **5b** and **5c** showed similar activity to the reference compounds **1** and **11** on Pf. K1
171 (EC_{50} = 0.2 and 0.12 μ M vs. 0.2 μ M). Moreover, their cytotoxicity on HepG2 was acceptable
172 (CC_{50} > 10 μ M). Thus, the selectivity index of **5c** is higher than that of its isotopic analogue **1** (SI
173 = 149 vs. 128).

174 Then, a second strategy was explored to increase the metabolic stability of the compounds. It
175 is well-known that the lipophilicity of a drug has a strong impact on various pharmacokinetic
176 parameters, including its biotransformation.[17] The introduction of a linear or a cyclic
177 alkylamine substituent at position 2 was explored in order to reduce their LogD, increase their
178 aqueous solubility and potentially enhance their metabolic stability. This approach has been
179 successfully employed in this series by introducing a diaminoalkyl chain at position 4, resulting
180 in an 100-fold improvement in aqueous solubility at pH 7.4, and a 6-fold enhancement in

181 microsomal stability, compared to compound **1**. [14] Thus, compounds bearing a diamine
182 (compound **5e**), a 4-aminoazetidine (compound **6a**) and a 3-aminopyrrolidine group
183 (compound **6b**) at position 2 were synthesized and evaluated. These compounds exhibited
184 calculated LogD_{7.4} values lower than compound **1** (between -0.4 and 1.55, vs. 3.73 for **1**). [20]
185 However, these modifications resulted in a loss of antiplasmodial activity (EC₅₀ > 9 μM). These
186 results suggest that the presence of a polar group at position 2 is unfavourable and that this
187 substituent occupies a hydrophobic pocket within the target. In addition, these modifications
188 led to some cytotoxicity against HepG2 cells. For example, compound **6a** showed high
189 cytotoxicity, with a CC₅₀ around 1 μM.

190 Finally, as the *tert*-butyl group at position 2 was previously identified as a sensitive site for
191 oxidation, the substitution of this substituent with a cyclic group was explored. Indeed, it has
192 been postulated that the reduction in the number of available conformations in a cyclic
193 template could potentially attenuate the rate of metabolism, compared to the acyclic
194 form. [21] A series of cycloalkylamines (compounds **5f** to **5i**) and cyclic amines (compounds **5j**
195 to **5n**) were introduced at position 2. Compounds with an aminocyclopropyl (**5f**),
196 aminocyclobutyl (**5g**) and aminocyclopentyl moiety (**5h**) showed an activity on *Pf.* K1 in the
197 micromolar range (IC₅₀ between 0.9 and 1.9 μM), only slightly lower than compound **1**.
198 Compound **5g** displayed a moderate selectivity index (SI = 12.7), whereas the two other
199 compounds showed some cytotoxicity against HepG2, particularly compound **5f** displaying a
200 CC₅₀ of 4 μM. The introduction of an aminocyclohexyl group (**5i**) resulted in a loss of activity,
201 suggesting that the size of this substituent is too large to interact with the target and a 5-
202 member ring is the maximum tolerated size.

203 The introduction of tertiary cyclic amines (compound **5j** to **5n**) was then studied, and the
204 influence of steric hindrance caused by the ring size was evaluated on the antiparasitic activity.
205 Compound **5j** bearing an azetidiny group could not be tested, due to its lack of solubility in
206 DMSO. A pyrrolidinyl group (compound **5k**) was tolerated in position 2, giving a moderately
207 active compound (IC₅₀ = 1.4 μM). Interestingly, the presence of an exocyclic NH group is not
208 necessary for activity against the erythrocytic stage of *P. falciparum*. Finally, as observed with
209 compound **5i**, introduction of a 6-membered cycle was not tolerated, compounds **5l** to **5n** were
210 inactive.

211

212 Table 1), resistant to chloroquine, pyrimethamine and sulfadoxine. All derivatives were
213 compared to Gamhepathiopine **1**. Chloroquine and doxycycline were included as reference
214 drugs.

215 In order to investigate the impact of the substitution of position 3 in this series of compounds,
216 compounds **10a-c** were evaluated on the erythrocytic stage of *P. falciparum*. Compounds **10a**
217 and **10b** were inactive ($EC_{50} > 12.5 \mu M$). On the other hand, **10c** showed very low activity on *P.*
218 *falciparum* compared to Gamhepathiopine **1** (EC_{50} of $4.2 \mu M$ vs. $0.2 \mu M$). Furthermore, this
219 substitution led to an increase in the cytotoxicity of the compounds, particularly for compound
220 **10b**, which exhibited a CC_{50} value of $6.3 \mu M$ against the HepG2 cell line. Hence, the presence
221 of an NH group at position 3 appears to be essential for the antiplasmodial activity of this series
222 of compounds and was consistently maintained in all other synthesized derivatives.

223 Then, we focused on the influence of modulating position 2 of the thienopyrimidone scaffold.
224 Initially, the introduction of a methylamine group in position 2 was considered in view of the
225 activity of different series of thieno[3,2-*d*]pyrimidine analogues proposed by González Cabrera
226 *et al.*, which showed strong activity on several strains of *P. falciparum*. [15,16] However, in our
227 hands, the 2-aminomethyl analogue **5a** was found to be inactive. This result demonstrates
228 that, despite the structural similarity with other reported antiplasmodial compounds,
229 Gamhepathiopine derivatives do not appear to share the same mechanism of action.

230 Then, as gamhepathiopine **1** was highly metabolized in the presence of female mouse
231 microsomes (half-life, $t_{1/2} = 11$ min) and the *tert*-butyl group at position 2 proved to be highly
232 sensitive to oxidation, the introduction of more stable groups was considered in order to
233 decrease metabolism at this position. In drug design, a common strategy involves replacing
234 chemical groups that are substrates of cytochromes with bioisosteres called metabolic
235 blockers, such as fluorine or deuterium atoms. Deuterium, a heavy and non-radioactive
236 isotope of hydrogen, has been officially recognized in medicinal chemistry since 2017,
237 following the FDA approval of the first deuterated drug (Deutetrabenazine), for the treatment
238 of Huntington's disease. [17] Deuterium is mainly used for its kinetic isotope effect. It
239 expresses twice the mass of hydrogen; therefore, the carbon-deuterium bond is more stable
240 and resistant to oxidative processes that may occur during phase I reactions of metabolism.
241 Additionally, deuterium exhibits steric and electronic properties similar to hydrogen.[18] This
242 alternative isostere effectively limits oxidation and improves the pharmacokinetic properties
243 of compounds, such as their half-life and clearance. On the other hand, the introduction of a
244 fluorine atom or fluorinated groups is a widely employed approach to address metabolic

245 stability liabilities. Fluorine possesses a Van der Waals radius similar close to hydrogen (1.47 Å
246 vs. 1.20 Å), and the strength of the carbon-fluorine bond exceeds that of the carbon-hydrogen
247 bond.[19] Consequently, phase I oxidation reactions are more difficult, without significantly
248 altering the structure of the compound. Therefore, to enhance the metabolic stability of
249 gamhepathiopine, introduction of a fluorine or deuterium atom(s) at position 2 was
250 considered. Thus, the deuterated analogues (**5b** and **5c**), respective bioisosteres of compounds
251 **11**[9] and **1**, as well as the fluorinated derivative **5d** were synthesized and evaluated. While
252 the monotrifluoromethyl analogue of **1** was inactive (compound **5d**), the deuterated
253 compounds **5b** and **5c** showed similar activity to the reference compounds **1** and **11** on Pf. K1
254 ($EC_{50} = 0.2$ and $0.12 \mu\text{M}$ vs. $0.2 \mu\text{M}$). Moreover, their cytotoxicity on HepG2 was acceptable
255 ($CC_{50} > 10 \mu\text{M}$). Thus, the selectivity index of **5c** is higher than that of its isotopic analogue **1** (SI
256 $= 149$ vs. 128).

257 Then, a second strategy was explored to increase the metabolic stability of the compounds. It
258 is well-known that the lipophilicity of a drug has a strong impact on various pharmacokinetic
259 parameters, including its biotransformation.[17] The introduction of a linear or a cyclic
260 alkylamine substituent at position 2 was explored in order to reduce their LogD, increase their
261 aqueous solubility and potentially enhance their metabolic stability. This approach has been
262 successfully employed in this series by introducing a diaminoalkyl chain at position 4, resulting
263 in an 100-fold improvement in aqueous solubility at pH 7.4, and a 6-fold enhancement in
264 microsomal stability, compared to compound **1**. [14] Thus, compounds bearing a diamine
265 (compound **5e**), a 4-aminoazetidine (compound **6a**) and a 3-aminopyrrolidine group
266 (compound **6b**) at position 2 were synthesized and evaluated. These compounds exhibited
267 calculated $\text{LogD}_{7.4}$ values lower than compound **1** (between -0.4 and 1.55 , vs. 3.73 for **1**). [20]
268 However, these modifications resulted in a loss of antiplasmodial activity ($EC_{50} > 9 \mu\text{M}$). These
269 results suggest that the presence of a polar group at position 2 is unfavourable and that this
270 substituent occupies a hydrophobic pocket within the target. In addition, these modifications
271 led to some cytotoxicity against HepG2 cells. For example, compound **6a** showed high
272 cytotoxicity, with a CC_{50} around $1 \mu\text{M}$.


273 Finally, as the *tert*-butyl group at position 2 was previously identified as a sensitive site for
274 oxidation, the substitution of this substituent with a cyclic group was explored. Indeed, it has
275 been postulated that the reduction in the number of available conformations in a cyclic
276 template could potentially attenuate the rate of metabolism, compared to the acyclic
277 form.[21] A series of cycloalkylamines (compounds **5f** to **5i**) and cyclic amines (compounds **5j**
278 to **5n**) were introduced at position 2. Compounds with an aminocyclopropyl (**5f**),

279 aminocyclobutyl (**5g**) and aminocyclopentyl moiety (**5h**) showed an activity on *Pf.* K1 in the
 280 micromolar range (IC_{50} between 0.9 and 1.9 μM), only slightly lower than compound **1**.
 281 Compound **5g** displayed a moderate selectivity index ($SI = 12.7$), whereas the two other
 282 compounds showed some cytotoxicity against HepG2, particularly compound **5f** displaying a
 283 CC_{50} of 4 μM . The introduction of an aminocyclohexyl group (**5i**) resulted in a loss of activity,
 284 suggesting that the size of this substituent is too large to interact with the target and a 5-
 285 member ring is the maximum tolerated size.

286 The introduction of tertiary cyclic amines (compound **5j** to **5n**) was then studied, and the
 287 influence of steric hindrance caused by the ring size was evaluated on the antiparasitic activity.
 288 Compound **5j** bearing an azetidiny group could not be tested, due to its lack of solubility in
 289 DMSO. A pyrrolidinyl group (compound **5k**) was tolerated in position 2, giving a moderately
 290 active compound ($IC_{50} = 1.4 \mu\text{M}$). Interestingly, the presence of an exocyclic NH group is not
 291 necessary for activity against the erythrocytic stage of *P. falciparum*. Finally, as observed with
 292 compound **5i**, introduction of a 6-membered cycle was not tolerated, compounds **5l** to **5n** were
 293 inactive.

294

295 **Table 1.** *In vitro* antiplasmodial activity (EC_{50}) of thienopyrimidones on the erythrocytic stage of a K1 *P.*
 296 *falciparum* strain and corresponding cytotoxicity (CC_{50}) on the human HepG2 cell line.



297

Compound	R ₁	R ₂	<i>P. falciparum</i> K1 EC ₅₀ (μM) ^a	HepG2 CC ₅₀ (μM) ^b	SI ^c
1 (Gamhepathiopine)	NHtBu	H	0.2 ± 0.02[9]	25.6 ± 3.1[9]	128
11 [9]	NH/Pr	H	0.8 ± 0.5[9]	49.4 ± 1.0[9]	62
5a	NHCH ₃	H	> 25	> 6.2	-
5b	NHCH(CD ₃) ₂	H	0.2 ± 0.07	> 10	> 50
5c	NHC(CD ₃) ₃	H	0.1 ± 0.07	17.9 ± 5.3	149
5d	NHC(CF ₃)(CH ₃) ₂	H	> 10	23.9 ± 1.4	> 10
5e	N=(CH ₂) ₃ N(CH ₃) ₂	H	9.8 ± 3.1	4.1 ± 1.8	0.42
5f		H	0.9 ± 0.1	4.0 ± 0.1	4.4
5g		H	1.1 ± 0.2	14.0 ± 2.8	12.7
5h		H	1.4 ± 0.2	> 7.8	> 5.6

5i		H	> 12.5	> 12.5	-
5j		H	NT ^d	NT ^d	-
5k		H	1.4 ± 0.5	> 3.1	> 2.1
5l		H	> 25	> 3.1	-
5m		H	> 10	3.6 ± 1.5	< 0.4
5n		H	> 25	8.7 ± 2.8	< 0.3
6a ^e		H	17.9 ± 0.1	1.3 ± 0.1	0.1
6b ^e		H	> 31.25	13.2 ± 2.1	< 0.4
10a	NHtBu	Ph	> 12.5	> 3.1	-
10b	NHtBu	Et	> 12.5	6.3	< 0.5
10c	NHtBu	iPr	4.2 ± 0.9	> 3.9	> 0.9
Chloroquine			0.8 ± 0.1[10]	30[9]	37.5
Doxycycline			5.0[9]	20[9]	4

^a EC₅₀: half-maximal effective concentration. The values are mean ± SD of three independent experiments.

^b CC₅₀: half-maximal cytotoxic concentration. The values are mean ± SD of three independent experiments.

^c Selectivity index (SI) was calculated according to the following formula: SI = CC₅₀ (HepG2)/EC₅₀.

^d NT: not tested due to low solubility in DMSO.

^e Isolated as a trifluoroacetate salt.

298
299
300
301
302
303

304 2.2.2. Hepatic-stage Antiplasmodial Activity and Cytotoxicity against Primary Simian 305 Hepatocytes

306 Then, seven compounds with an EC₅₀ below 1.5 μM on the erythrocytic stage of *P. falciparum*
307 were selected for further studies. Thus, thienopyrimidines were evaluated for their ability to
308 inhibit hepatic infection caused by the rodent malaria parasite *P. berghei* in simian
309 hepatocytes. Their cytotoxicity was also determined on primary simian hepatocytes. The
310 results are presented in Table .

311 **Table 2.** *In vitro* activity (EC₅₀) against the hepatic stage of *P. berghei* parasites and cytotoxicity (CC₅₀)
312 against primary simian hepatocytes of selected thieno[3,2-*d*]pyrimidones.

Compound	<i>P. berghei</i> EC ₅₀ (μM) ^a	Primary simian hepatocytes CC ₅₀ (μM) ^b
----------	---	---

1 (Gamhepathiopine)	24.3 ± 1.6[10]	> 200[10]
11	55.6 ± 10.4	> 200
5b	15.9 ± 2.3	> 100
5c	13.7 ± 1.3	> 100
5f	5.5 ± 0.8	> 100
5g	11.2 ± 1.2	> 100
5h	10.5 ± 1.3	> 100
5k	> 100	> 200

^a EC₅₀: half-maximal effective concentration. The values are mean ± SD of three independent experiments.

^b CC₅₀: half-maximal cytotoxic concentration. The values are mean ± SD of three independent experiments.

Except compounds **11** and **5k**, all other compounds showed higher activity against the hepatic stage of *P. berghei* than Gamhepathiopine **1**. Thus, the activity of deuterated analogues of **1** and **11**, namely compound **5b** and **5c**, was increased by a factor of 1.5 to 4, indicating that the introduction of deuterium atoms is favourable for activity. Interestingly, the introduction of a 3- to 5-membered carbocycle at position 2 increased the activity against the hepatic stage. Among this series, compound **5f** with an aminocyclopropyl substituent, showed the highest activity, with an EC₅₀ of 5.56 μM. Finally, while the presence of a NH group was not necessary to maintain erythrocytic activity, its removal was deleterious for the hepatic activity. These results suggest that this compound may have a different mechanism of action than compound **1**. Lastly, none of the selected compounds showed cytotoxicity against simian hepatocytes at the highest dose tested (EC₅₀ > 100 μM).

2.2.3. Characterization of Drug-like Properties of Compounds **5b-c** and **5f-h**

Deuterated compounds **5b** and **5c**, as well as 3-, 4- and 5-membered aminocarbocyclic derivatives **5f**, **5g** and **5h** were selected to assess their stability in the presence of female mouse microsomes. Results are reported in Table 3. Deuterated analogues (compounds **5b** and **5c**, respectively) showed weak microsomal stability, similar to the reference compounds **1** and **11** (T_{1/2} close to 10 minutes). Thus, this strategy to increase the metabolic stability of the thienopyrimidones proved to be inefficient for this series of compounds. However, the rigidification of the alkyl substituent by a carbocycle increased the metabolic stability by a factor of 1.5 to 3.8, compared to Gamhepathiopine **1**. Notably, compounds **5g** and **5h** showed half-lives of 29 and 38 minutes, respectively. Consequently, the intrinsic clearance of these two compounds decreased (Cl_{int} > 58 μL/min/mg vs. Cl_{int} > 240 for compound **1**). Considering both the antiplasmodial activities, cytotoxicity and microsomal stability, compound **5g** was selected for further characterizations. Indeed, the aminocyclobutyl derivative was preferred

343 because it displayed a better activity against the erythrocytic stage of *P. falciparum* and lower
 344 cytotoxicity on HepG2 compared to the aminocyclopentyl-substituted derivative ($EC_{50} = 1.1$
 345 μM and $CC_{50} = 14.0 \mu\text{M}$ vs. $EC_{50} = 1.4 \mu\text{M}$ and $CC_{50} > 7.8 \mu\text{M}$).

346 Since the *in-vivo* activity of Gamhepathiopine **1** was studied in its hydrochloride salt form,[8]
 347 compound **5g** was converted into this form after treatment with a hydrochloric acid solution
 348 in dioxane. The activity of the hydrochloride salt of **5g** was first evaluated toward both the
 349 erythrocytic and hepatic parasite stages, along with its potential cytotoxicity against the HepG2
 350 cell line and primary simian hepatocytes. As expected, no significant differences were found
 351 (data not shown). However, the introduction of an aminocyclobutyl moiety decreased the
 352 aqueous solubility of the thienopyrimidone ($1.4 \mu\text{M}$ vs. $7.9 \mu\text{M}$ for the reference compound),
 353 even if **5g.HCl** was less hydrophobic than compound **1.HCl**, as indicated by its lower $\text{LogD}_{7.4}$
 354 (3.16 vs. 4.10). Permeability at different pH was then further evaluated to test the ability of
 355 thieno[3,2-*d*]pyrimidinones to cross membrane barriers to be readily distributed. While no
 356 value could be measured at pH 6.0 because compound **5g** precipitated in these conditions, this
 357 compound diffused at pH 5.0 and 7.4, with an effective permeability coefficient of 180.5 and
 358 43.4 nm/s , respectively, better values than those obtained with the reference compound **1**
 359 (Table 4). Finally, the affinity for hERG potassium channels was determined to assess the
 360 cardiac toxicity of these thienopyrimidinones. Gamhepathiopine **1.HCl**, previously studied, did
 361 not show affinity for hERG channels. Similarly, its aminocyclobutyl analog **5g.HCl** did not cause
 362 significant inhibition of these channels ($IC_{50} > 100 \mu\text{M}$, Table 5).

363 **Table 3.** Microsomal stability in presence of female mouse liver microsomes of selected compounds.

Compound	Microsomal stability	
	$T_{1/2}$ (min)	Cl_{int} ($\mu\text{L}/\text{min}/\text{mg}$)
1	10[8]	240[14]
11	11	214
5b	11	214
5c	8.5	209
5f	15	136
5g	29	78
5h	38	58

364

365 **Table 4.** Physicochemical profile, permeability in the PAMPA gastrointestinal assay and hERG affinity of
 366 selected thieno[3,2-*d*]pyrimidines.

Cpd	Solubility ^a (μM)	CHI Log D ^b	Pe (nm/s) ^c			hERG IC_{50} (μM)
			pH			
			5.0	6.0	7.4	
1.HCl	7.9 ± 0.8 [13]	4.10 [14]	0[13]	0[13]	4.6 ± 7.2 [13]	> 100
5g.HCl	1.4 ± 0.9	3.16	180.5 ± 61.8	ND ^d	43.6 ± 17.8	> 100

367 ^a Solubility was determined in phosphate-buffered saline. Values are the mean \pm SD of three independent
368 experiments.
369 ^b CHI: Chromatographic hydrophobicity index at pH = 7.4.
370 ^c Determined using a parallel artificial membrane permeability of gastrointestinal tract (PAMPA-GIT) assay.
371 ^d Not determined due to a too low solubility of the tested compound.
372
373

374 3. Conclusions

375 In conclusion, this study aimed to explore different substitutions at positions 2 and 3 of the
376 thienopyrimidinone scaffold, to improve the understanding of the antiplasmodial SAR of this
377 compound series and to enhance its metabolic stability. While substitutions at position 3 led
378 to inactive compounds, indicating the essential role of an NH group at this position, several
379 modifications at position 2 were found to be tolerated. The introduction of deuterated
380 moieties did not alter activity against the erythrocytic stage of *P. falciparum* and has even
381 slightly increased activity against the liver stage of *P. berghei*, resulting in active compounds
382 **5b** and **5c**, with favourable selectivity indices. On the other hand, the introduction of a fluorine
383 atom had a detrimental effect, while the introduction of cyclic groups, such as
384 aminocyclopropyl, aminocyclobutyl, and aminocyclopentyl moieties, resulted in compounds
385 **5f**, **5g**, and **5h** with activity against *P. falciparum* K1 in the micromolar range. The stability of
386 the compounds in the presence of microsomes revealed that deuterated analogues did not
387 exhibit improved metabolic stability, while the introduction of carbocycles increased the
388 metabolic stability, compared to Gamhepathiopine **1**. Notably, compound **5g** displayed a 3-
389 fold increased half-life compared to **1**, a promising activity against both the erythrocytic and
390 hepatic stages of *Plasmodium*, and no affinity for hERG cardiac channels. Further studies and
391 evaluations are warranted to explore its potential as a candidate for antiparasitic drug
392 development.

393

394 4. Experimental part

395 4.1. Chemistry

396 4.1.1. Material and Methods

397 Commercial reagents and solvents were used without further purification. The synthesized
398 products were purified by chromatography on silica gel (40–63 μ m) or by preparative HPLC on
399 an apparatus equipped with a Delta Pack C18 radial compression column (100 mm x 40 mm,
400 15 μ m, 100 Å) at a wavelength of 214 nm, at a flow rate of 28 mL/min with a variable elution
401 gradient from X % A (H₂O + 0.1% TFA) to X + 30% B (ACN + 0.1% TFA) in 30 min. The purest
402 fractions are pooled, freeze-dried, and lyophilized to give the final compounds. LC/MS analyses

403 were recorded on a Quattro microTMESI triple quadrupole mass spectrometer (ESI+
404 electrospray ionization mode) or on a Micromass ZQ spectrometer (ESI+ electrospray
405 ionization mode), coupled to an Alliance HPLC system (Waters, Milford, CT, USA) equipped
406 with a Chromolith High Resolution RP-18e column (25 x 4.6mm), with the samples being
407 previously separated using a gradient from 100% (H₂O + 0.1% HCO₂H) to 100% (ACN + 0.1%
408 HCO₂H) in 3 min at a flow rate of 3 mL/min and with UV detection at 214 nm. UPLC/MS analyses
409 were recorded with an Acquity H-Class UPLC system, coupled to a Waters SQ Detector-2 mass
410 spectrometer (Waters, Milford, CT, USA). Chromatographic separation was carried out under
411 the same conditions as above using a Waters Acquity UPLC BEC C18 column (100 x 2.1 mm, 1.5
412 μm). High-resolution mass spectrometry (HRMS) analyses were performed with a time-of-
413 flight (TOF) spectrometer coupled to a positive electrospray ionization (ESI) source. The
414 elemental analysis was realized with a Elementar Vario Micro Cube. The NMR spectra were
415 recorded on a Brüker 400, 500, or 600 spectrometers. Chemical shifts are expressed in parts
416 per million (ppm) relative to the residual signal of the deuterated solvent used (CDCl₃, DMSO-
417 d₆, MeOH-d₃, ACN-d₃), and the coupling constants J are expressed in Hertz. The multiplicities
418 are designated as singlet (s), broad singlet (bs) doublet (d), doublet of doublet (dd), triplet (t),
419 quadruplet (q), quintuplet (qt), sextuplet (st), or multiplet (m). Compounds **1**, **2** and **11** were
420 synthesized according to the previous reported procedure and its physical characteristics
421 agreed with the published data.[9]

422

423 4.1.2. General Procedure for the Synthesis of 2-Substituted-thieno[3,2-*d*]pyrimidines **5a-** 424 **p**.

425 To a solution of aminothiophene **2** in DMF was added ethoxycarbonyl isothiocyanate (1 eq.).
426 The solution was stirring at 30°C for 2h. During this reaction, the thiourea carbamate
427 intermediate **3** was formed and was not isolated. Then, triethylamine (3 eq.), the appropriate
428 amine (2 eq.) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, hydrochloride (EDCI, HCl)
429 (1.2 eq.) were added. The reaction mixture was stirred overnight at room temperature to
430 generate the guanidine intermediate **4**. The solution was then heated under reflux (170°C) for
431 1 to 2h. The solvent was removed under reduced pressure and the crude was purified by the
432 appropriate method.

433

434 4.1.2.1. 2-Methylamino-6-(*p*-tolyl)thieno[3,2-*d*]pyrimidin-4(3*H*)-one (**5a**). Following the
435 general procedure, using **2** (500 mg, 2.022 mmol), ethoxycarbonyl isothiocyanate (265 mg,

436 2.022 mmol, 0.24 mL), triethylamine (614 mg, 6.065 mmol, 0.84 mL), methylamine (314 mg,
437 4.044 mmol, 0.35 mL), EDCI.HCl (465 mg, 2.426 mmol). After addition of water in the reaction
438 mixture, the obtained precipitate was filtered and washed with Et₂O. The desired compound
439 was obtained as a green powder (422 mg, 77%). ¹H NMR (500 MHz, DMSO-*d*₆): δ 7.67 (d, 2H,
440 CH_{ar}, J = 8.1 Hz), 7.35 (s, 1H H-thiophene), 7.27 (d, 2H, CH_{ar}, J = 8.0 Hz), 7.03 (s, 2H, NH), 3.36
441 (s, 3H, CH₃N), 2.34 (s, 3H, CH₃); ¹³C NMR (500 MHz, DMSO-*d*₆): δ 158.7, 157.4, 155.0, 150.4,
442 139.1, 130.3, 129.8, 125.8, 118.9, 110.1, 28.2, 20.9; LC/MS: tr-LC/MS = 1.18 min, [M+H]⁺ =
443 272.0; HR-MS (ESI) C₁₄H₁₄N₃OS calculated: 272.0852 [M+H]⁺, found: 272.0860.

444
445 4.1.2.2. 2-(Isopropylamino-*d*₆)-6-(*p*-tolyl)thieno[3,2-*d*]pyrimidin-4(3*H*)-one (**5b**). Following the
446 general procedure, using **2** (400 mg, 1.617 mmol), ethoxycarbonyl isothiocyanate (212 mg,
447 1.617 mmol, 0.19 mL), triethylamine (491 mg, 4.852 mmol, 0.67 mL), isopropylamine-*d*₆ (211
448 mg, 3.235 mmol, 0.28 mL), EDCI.HCl (372 mg, 1.941 mmol). After addition of water in the
449 reaction mixture, the obtained precipitate was filtered, washed with Et₂O and recrystallized
450 with ACN. The desired compound was obtained as an off-white powder (323 mg, 65%). ¹H NMR
451 (500 MHz, DMSO-*d*₆): δ 10.60 (s, 1H, NH), 7.66 (d, 2H, CH_{ar}, J = 8.1 Hz), 7.47 (s, 1H, H-
452 thiophene), 7.27 (d, 2H, CH_{ar}, J = 8.0 Hz), 6.11 (d, 1H, NHCH, J = 7.6 Hz), 3.99 (d, 1H, CHNH, J =
453 7.5 Hz), 2.33 (s, 3H, CH₃-tolyl); ¹³C NMR (500 MHz, DMSO-*d*₆): δ 160.5, 157.6, 152.7, 150.2,
454 139.0, 130.3, 129.7, 125.7, 119.7, 111.0, 41.8, 20.8; LC/MS: tr-LC/MS = 1.60 min, [M+H]⁺ =
455 306.2; HR-MS (ESI) C₁₆H₁₂D₆N₃OS calculated: 306.1542 [M+H]⁺, found: 306.1557.

456
457 4.1.2.3. 2-(*Tert*-butylamino-*d*₉)-6-(*p*-tolyl)thieno[3,2-*d*]pyrimidin-4(3*H*)-one (**5c**). Following the
458 general procedure, using **2** (250 mg, 1.011 mmol), ethoxycarbonyl isothiocyanate (133 mg,
459 1.011 mmol, 0.12 mL), triethylamine (307 mg, 3.033 mmol, 0.42 mL), *tert*-butylamine-*d*₉ (166
460 mg, 2.022 mmol, 0.18 mL), EDCI.HCl (233 mg, 1.213 mmol). After addition of water in the
461 reaction mixture, the obtained precipitate was filtered, washed with Et₂O and recrystallized
462 with ACN. The desired compound was obtained as a white powder (200 mg, 61%). ¹H NMR
463 (500 MHz, DMSO-*d*₆): δ 10.46 (s, 1H, NH), 7.68 (d, 2H, CH_{ar}, J = 7.0 Hz), 7.46 (s, 1H, H-
464 thiophene), 7.26 (d, 2H, CH_{ar}, J = 7.3 Hz), 6.07 (s, 1H, NH), 2.33 (s, 3H, CH₃-tolyl); ¹³C NMR (500
465 MHz, DMSO-*d*₆): δ 160.3, 157.6, 152.3, 150.2, 139.0, 130.3, 129.8, 125.8, 120.0, 111.0, 50.5,
466 20.9; LC/MS: tr-LC/MS = 1.80 min, [M+H]⁺ = 323.2; HR-MS (ESI) C₁₇H₁₁D₉N₃OS calculated:
467 323.1887 [M+H]⁺, found: 323.1898.

468

469 4.1.2.4. 2-(1,1,1-Trifluoro-2-methylpropan-2-yl)amino)-6-(*p*-tolyl)thieno[3,2-*d*]pyrimidin-
470 4(3*H*)-one (**5d**). Following the general procedure, using **2** (300 mg, 1.213 mmol),
471 ethoxycarbonyl isothiocyanate (164 mg, 1.213 mmol, 0.15 mL), triethylamine (368 mg, 3.639
472 mmol, 0.51 mL), 2,2,2-trifluoro-1,1-dimethyl-ethylamine (315 mg, 2.426 mmol, 0.28 mL),
473 EDCI.HCl (279 mg, 1.456 mmol). The crude was partitioned in water and DCM. Organic layer
474 was washed with brine, dried with MgSO₄, filtered and concentrated under reduce pressure.
475 The crude was purified by chromatography on silica gel (eluent: 99.5/0.5 DCM/MeOH to
476 97/03). The solid collected was recrystallized with EtOH to afford the desired compound as an
477 off-white solid (213 mg, 48%). ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.62 (s, 1H, NH), 7.69 (d, 2H,
478 CH_{ar}, *J* = 8.2 Hz), 7.49 (s, 1H, H-thiophene), 7.28 (d, 2H, CH_{ar}, *J* = 8.0 Hz), 6.56 (s, 1H, NH), 2.34
479 (s, 3H, CH₃-tolyl), 1.68 (s, 6H, (CH₃)₂); ¹³C NMR (400 MHz, DMSO-*d*₆): δ 159.4, 157.2, 151.6,
480 150.6, 139.2, 130.1, 129.8, 127.0 (q, 1J_{CF} = 285.9) Hz), 125.8, 120.0, 112.5, 56.8 (q, 2J_{CF} = 27.6
481 Hz), 21.0, 20.9; ¹⁹F NMR (400 MHz, DMSO-*d*₆): δ -79.35; LC/MS: tr-LC/MS = 2.07 min, [M+H]⁺
482 = 368.2; HR-MS (ESI) C₁₇H₁₇F₃N₃OS calculated: 368.1039 [M+H]⁺, found: 368.1037.

483
484 4.1.2.5. 2-((3-Dimethylamino)propyl)imino)-6-(*p*-tolyl)-2,3-dihydrothieno[3,2-*d*]pyrimidin-
485 4(3*H*)-one (**5e**). Following the general procedure, using **2** (250 mg, 1.011 mmol),
486 ethoxycarbonyl isothiocyanate (133 mg, 1.011 mmol, 0.12 mL), triethylamine (307 mg, 3.033
487 mmol, 0.42 mL), 3-dimethylaminopropylamine (207 mg, 2.022 mmol, 0.26 mL), EDCI.HCl (233
488 mg, 1.213 mmol). After addition of water in the reaction mixture, the obtained precipitate was
489 filtered, washed with ACN. The desired compound was obtained off-white solid (206 mg, 60%)
490 ; ¹H NMR (500 MHz, DMSO-*d*₆): δ 7.66 (d, 2H, CH_{ar}, *J* = 8.1 Hz), 7.34 (s, 1H, H-thiophene), 7.29-
491 7.26 (m, 4H, CH_{ar} + NH), 3.96-3.93 (m, 2H, CH₂N), 2.34 (s, 3H, CH₃-tolyl), 2.27-2.24 (m, 2H,
492 CH₂N), 2.17 (s, 6H, (CH₃)₂), 1.81-1.76 (m, 2H, CH₂); ¹³C NMR (500 MHz, DMSO-*d*₆): δ 158.9,
493 157.6, 155.1, 150.4, 139.1, 130.3, 129.8, 125.9, 119.0, 110.4, 55.1, 44.6, 39.3, 25.1, 20.9; HR-
494 MS (ESI) C₁₈H₂₂N₄OS calculated: 343.1601 [M+H]⁺, found: 343.1594.

495
496 4.1.2.6. 2-(Cyclopropylamino)-6-(*p*-tolyl)-thieno[3,2-*d*]pyrimidin-4(3*H*)-one (**5f**). Following the
497 general procedure, using **2** (300 mg, 1.213 mmol), ethoxycarbonyl isothiocyanate (164 mg,
498 1.213 mmol, 0.15 mL), triethylamine (368 mg, 3.639 mmol, 0.51 mL), cyclopropylamine (139
499 mg, 2.426 mmol, 0.17 mL), EDCI.HCl (279 mg, 1.456 mmol). After addition of water in the
500 reaction mixture, the obtained precipitate was filtered, washed with Et₂O to afford a green
501 powder (229 mg, 63%); ¹H NMR (500 MHz, DMSO-*d*₆, T = 373 K): δ 7.65 (d, 2H, CH_{ar}, *J* = 7.8 Hz),

502 7.39 (s, 1H, H-thiophene), 7.28 (d, 2H, CH_{ar}, *J* = 7.6 Hz), 6.60 (s, 1H, NH), 2.76-2.75 (m, 1H, CH),
503 2.34 (s, 3H, CH₃-tolyl), 0.77-0.76 (m, 2H, CH₂), 0.55-0.52 (m, 2H, CH₂); ¹³C NMR (500 MHz,
504 DMSO-d₆, T = 373 K): δ 159.4, 157.2, 154.0, 150.0, 138.5, 130.0, 129.2, 125.4, 119.0, 111.5,
505 22.9, 20.2, 6.2; UPLC/MS: t_r = 2.76 min, [M+H]⁺ = 298.1; HR-MS (ESI) C₁₆H₁₆N₃OS calculated:
506 298.1009 [M+H]⁺, found: 298.1021.

507
508 4.1.2.7. 2-(Cyclobutylamino)-6-(*p*-tolyl)-thieno[3,2-*d*]pyrimidin-4(3*H*)-one (**5g**). Following the
509 general procedure, using **2** (300 mg, 1.213 mmol), ethoxycarbonyl isothiocyanate (164 mg,
510 1.213 mmol, 0.15 mL), triethylamine (368 mg, 3.639 mmol, 0.51 mL), cyclobutylamine (173
511 mg, 2.426 mmol, 0.21 mL), EDCI.HCl (279 mg, 1.456 mmol). After addition of water in the
512 reaction mixture, the obtained precipitate was filtered, washed with Et₂O and recrystallized
513 with ACN. A white powder was obtained (150 mg, 40%); ¹H NMR (500 MHz, DMSO-d₆): δ 10.72
514 (s, 1H, NH), 7.66 (d, 2H, CH_{ar}, *J* = 8.0 Hz), 7.45 (s, 1H, H-thiophene), 7.26 (d, 2H, CH_{ar}, *J* = 7.9 Hz),
515 6.58 (s, 1H, NH), 4.36-4.29 (m, 1H, CHNH), 2.33 (s, 3H, CH₃-tolyl), 2.30-2.26 (m, 2H, CH₂), 1.94-
516 1.86 (m, 2H, CH₂), 1.70-1.62 (m, 2H, CH₂); ¹³C NMR (500 MHz, DMSO-d₆): δ 160.4, 157.7, 152.4,
517 150.3, 139.1, 130.3, 129.8, 125.8, 119.6, 111.3, 45.5, 30.6, 20.9, 14.7; LC/MS: t_r = 1.65 min,
518 [M+H]⁺ = 312.1; HR-MS (ESI) C₁₇H₁₈N₃OS calculated: 312.1165 [M+H]⁺, found: 312.1182.

519
520 4.1.2.8. 2-(Cyclopentylamino)-6-(*p*-tolyl)-thieno[3,2-*d*]pyrimidin-4(3*H*)-one (**5h**). Following the
521 general procedure, using **2** (300 mg, 1.213 mmol), ethoxycarbonyl isothiocyanate (164 mg,
522 1.213 mmol, 0.15 mL), triethylamine (368 mg, 3.639 mmol, 0.51 mL), cyclopentylamine (207
523 mg, 2.426 mmol, 0.24 mL), EDCI.HCl (279 mg, 1.456 mmol). After addition of water in the
524 reaction mixture, the obtained precipitate was filtered and washed with Et₂O. An off-white
525 powder was obtained (224 mg, 57%); ¹H NMR (400 MHz, DMSO-d₆): δ 10.53 (s, 1H, NH), 7.67
526 (d, 2H, CH_{ar}, *J* = 8.2 Hz), 7.47 (s, 1H, H-thiophene), 7.27 (d, 2H, CH_{ar}, *J* = 8.2 Hz), 6.30 (d, 1H,
527 NHCH, *J* = 7.0 Hz), 4.15 (sx, 1H, CH, *J* = 6.6 Hz), 2.34 (s, 3H, CH₃-tolyl), 1.98-1.90 (m, 2H, CH₂),
528 1.70-1.52 (m, 4H, CH₂), 1.48-1.41 (m, 2H, CH₂); ¹³C NMR (400 MHz, DMSO-d₆): δ 160.5, 157.5,
529 153.0, 150.2, 139.0, 130.2, 129.7, 125.7, 119.7, 111.0, 52.0, 32.5, 23.1, 20.8; LC/MS: t_r = 1.75
530 min, [M+H]⁺ = 326.1; HR-MS (ESI) C₁₈H₂₀N₃OS calculated: 326.1322 [M+H]⁺, found: 326.1334.

531
532 4.1.2.9. 2-(Cyclohexylamino)-6-(*p*-tolyl)-thieno[3,2-*d*]pyrimidin-4(3*H*)-one (**5h**). Following the
533 general procedure, using **2** (300 mg, 1.213 mmol), ethoxycarbonyl isothiocyanate (164 mg,
534 1.213 mmol, 0.15 mL), triethylamine (368 mg, 3.639 mmol, 0.51 mL), cyclohexylamine (241

535 mg, 2.426 mmol, 0.28 mL), EDCI.HCl (279 mg, 1.456 mmol). After addition of water in the
536 reaction mixture, the obtained precipitate was filtered and washed with Et₂O. The crude was
537 then purified by chromatography on silica (eluent: 98/02 DCM/MeOH to 95/05). The desired
538 compound was a white solid (326 mg, 79%); ¹H NMR (400 MHz, DMSO-d₆): δ 10.56 (s, 1H, NH),
539 7.67 (d, 2H, CH_{ar}, *J* = 8.1 Hz), 7.48 (s, 1H, H-thiophene), 7.27 (d, 2H, CH_{ar}, *J* = 8.0 Hz), 6.20 (d,
540 1H, NHCH, *J* = 6.9 Hz), 3.77-3.72 (m, 1H, CH), 2.34 (s, 3H, CH₃-tolyl), 1.93-1.90 (m, 2H, CH₂),
541 1.69-1.67 (m, 2H, CH₂), 1.57-1.55 (m, 1H, CH₂), 1.38-1.31 (m, 2H, CH₂), 1.27-1.21 (m, 3H, CH₂);
542 ¹³C NMR (400 MHz, DMSO-d₆): δ 160.5, 157.6, 152.6, 150.2, 139.0, 130.3, 129.7, 125.7, 119.7,
543 110.9, 48.6, 32.3, 25.2, 24.2, 20.8; UPLC/MS: t_r = 3.66 min, [M+H]⁺ = 340.1; HR-MS (ESI) C₁₉H₂₂
544 N₃OS calculated: 340.1478 [M+H]⁺, found: 340.1495.

545
546 4.1.2.10. 2-(Azetidin-1-yl)-6-(*p*-tolyl)-thieno[3,2-*d*]pyrimidin-4(3*H*)-one (**5j**). Following the
547 general procedure, using **2** (1 g, 4.044 mmol), ethoxycarbonyl isothiocyanate (0.530 g, 4.044
548 mmol, 0.48 mL), triethylamine (1.228 g, 12.13 mmol, 1.69 mL), azetidine (0.462 g, 8.087 mmol,
549 0.54 mL), EDCI.HCl (0.930 g, 4.852 mmol). After addition of water in the reaction mixture, the
550 obtained precipitate was filtered, washed with Et₂O and recrystallized with ACN. The desired
551 compound was obtained as a green powder (0.473 g, 39%); ¹H NMR (500 MHz, DMSO-d₆, T =
552 373 K) δ 11.04 (s, 1H, NH), 7.63 (d, 2H, CH_{ar}, *J* = 8.2 Hz), 7.36 (s, 1H, H-thiophene), 7.28 (d, 2H,
553 CH_{ar}, *J* = 7.9 Hz), 4.11-4.08 (m, 4H, CH₂N), 2.36 (s, 3H, CH₃-tolyl), 2.34-2.28 (m, 2H, CH₂); ¹³C
554 NMR (500 MHz, DMSO-d₆, T = 373 K): δ 159.5, 157.9, 154.4, 150.0, 138.5, 130.1, 129.2, 125.4,
555 119.0, 111.2, 50.3, 20.2, 15.4; LC/MS: t_r = 1.19 min, [M+H]⁺ = 298.0; HR-MS (ESI) C₁₆H₁₆N₃OS
556 calculated: 298.1 [M+H]⁺, found: 298.1.

557
558 4.1.2.12. 2-(Pyrrolidin-1-yl)-6-(*p*-tolyl)-thieno[3,2-*d*]pyrimidin-4(3*H*)-one (**5k**). Following the
559 general procedure, using **2** (1 g, 4.044 mmol), ethoxycarbonyl isothiocyanate (0.530 g, 4.044
560 mmol, 0.48 mL), triethylamine (1.228 g, 12.13 mmol, 1.69 mL), pyrrolidine (0.575 g, 8.087
561 mmol, 0.66 mL), EDCI.HCl (0.930 g, 4.852 mmol). After addition of water in the reaction
562 mixture, the obtained precipitate was filtered, washed with ACN. The desired compound was
563 obtained as a green powder (0.732 g, 58%); ¹H NMR (500 MHz, DMSO-d₆): δ 10.60 (s, 1H, NH),
564 7.63 (d, 2H, CH_{ar}, *J* = 8.2 Hz), 7.33 (s, 1H, H-thiophene), 7.28 (d, 2H, CH_{ar}, *J* = 8.0 Hz), 3.53-3.50
565 (m, 4H, CH₂NH), 2.36 (s, 3H, CH₃-tolyl), 1.96-1.93 (m, 4H, CH₂); ¹³C NMR (500 MHz, DMSO-d₆):
566 δ 160.1, 158.1, 151.8, 149.9, 138.4, 130.1, 129.2, 125.3, 119.0, 110.2, 46.3, 24.2, 20.2; LC/MS:

567 $t_r = 1.23$ min, $[M+H]^+ = 312.1$; HR-MS (ESI) $C_{17}H_{18}N_3OS$ calculated: 312.1171 $[M+H]^+$, found:
568 312.1169.

569

570 4.1.2.13. 2-(Piperidin-1-yl)-6-(*p*-tolyl)-thieno[3,2-*d*]pyrimidin-4(3*H*)-one (**5l**). Following the
571 general procedure, using **2** (1 g, 4.044 mmol), ethoxycarbonyl isothiocyanate (0.530 g, 4.044
572 mmol, 0.48 mL), triethylamine (1.228 g, 12.13 mmol, 1.69 mL), piperidine (0.689 g, 8.087
573 mmol, 0.799 mL), EDCI.HCl (0.930 g, 4.852 mmol). After addition of water in the reaction
574 mixture, the obtained precipitate was filtered, washed with Et_2O to afford a green powder
575 (0.743 g, 56%); 1H NMR (500 MHz, $DMSO-d_6$, $T = 373$ K): δ 10.91 (s, 1H, NH), 7.64 (d, 2H, CH_{ar} ,
576 $J = 8.0$ Hz), 7.35 (s, 1H, H-thiophene), 7.28 (d, 2H, CH_{ar} , $J = 8.0$ Hz), 3.62-3.60 (m, 4H, CH_2), 2.36
577 (s, 3H, CH_3 -tolyl), 1.64-1.32 (m, 2H, CH_2), 1.59-1.56 (m, 4H, CH_2); ^{13}C NMR (500 MHz, $DMSO-d_6$,
578 $T = 373$ K): δ 159.8, 158.2, 153.3, 150.1, 138.5, 130.1, 129.2, 125.4, 119.2, 110.6, 45.6, 24.6,
579 23.4, 20.2; LC/MS: $t_r = 1.77$ min, $[M+H]^+ = 326.1$; HR-MS (ESI) $C_{18}H_{20}N_3OS$ calculated: 326.1327
580 $[M+H]^+$, found: 326.1324.

581

582 4.1.2.14. 2-Morpholino-6-(*p*-tolyl)-thieno[3,2-*d*]pyrimidin-4(3*H*)-one (**5m**). Following the
583 general procedure, using **2** (250 mg, 1.011 mmol), ethoxycarbonyl isothiocyanate (133 mg,
584 1.011 mmol, 0.12 mL), triethylamine (307 mg, 3.033 mmol, 0.42 mL), morpholine (176 mg,
585 2.022 mmol, 0.18 mL), EDCI.HCl (233 mg, 1.213 mmol). After addition of water in the reaction
586 mixture, the obtained precipitate was filtered, washed with Et_2O . The desired compound was
587 obtained as a green powder (242 mg, 73%); 1H NMR (500 MHz, $DMSO-d_6$, $T = 373$ K): δ 11.07
588 (s, 1H, NH), 7.65 (d, 2H, CH_{ar} , $J = 8.0$ Hz), 7.38 (s, 1H, H-thiophene), 7.29 (d, 2H, CH_{ar} , $J = 8.0$ Hz),
589 3.70-3.68 (m, 4H, CH_2N), 3.61-3.60 (m, 4H, CH_2O), 2.36 (s, 3H, CH_3 -tolyl); ^{13}C NMR (500 MHz,
590 $DMSO-d_6$, $T = 373$ K): δ 159.0, 158.2, 153.6, 150.3, 138.6, 130.0, 129.3, 125.4, 119.1, 111.6
591 65.2, 45.2, 20.3; LC/MS: $t_r = 1.39$ min, $[M+H]^+ = 328.2$; HR-MS (ESI) $C_{17}H_{18}N_3O_2S$ calculated:
592 328.1114 $[M+H]^+$, found: 328.1119.

593

594 4.1.2.15. 2-(4-Methylpiperazin-1-yl)-6-(*p*-tolyl)-thieno[3,2-*d*]pyrimidin-4(3*H*)-one (**5n**).
595 Following the general procedure, using **2** (250 mg, 1.011 mmol), ethoxycarbonyl
596 isothiocyanate (133 mg, 1.011 mmol, 0.12 mL), triethylamine (307 mg, 3.033 mmol, 0.42 mL),
597 1-methylpiperazine (203 mg, 2.022 mmol, 0.22 mL), EDCI.HCl (233 mg, 1.213 mmol). After
598 addition of water in the reaction mixture, the obtained precipitate was filtered, washed with
599 Et_2O . The desired compound was obtained as a yellow powder (210 mg, 61%); 1H NMR (500

600 MHz, DMSO- d_6): δ 11.38 (s, 1H, NH), 7.67 (d, 2H, CH_{ar} , $J = 8.1$ Hz), 7.48 (s, 1H, H-thiophene),
601 7.28 (d, 2H, CH_{ar} , $J = 7.9$ Hz), 3.59-3.57 (m, 4H, CH_2N), 2.37-2.35 (m, 4H, CH_2NCH_3), 2.34 (s, 3H,
602 CH_3 -tolyl), 2.20 (s, 3H, CH_3N); ^{13}C NMR (500 MHz, DMSO- d_6): δ 159.9, 158.8, 153.8, 150.6,
603 139.2, 130.2, 129.8, 125.9, 119.6, 111.5, 54.1, 45.7, 45.0, 20.9; UPLC/MS: $t_r = 2.21$ min, $[M+H]^+$
604 = 341.2; HR-MS (ESI) $C_{18}H_{21}N_4OS$ calculated: 341.1436 $[M+H]^+$, found: 341.1438.

605

606 4.1.2.16. *Tert*-butyl 3-((4-oxo-6-(*p*-tolyl)-3,4-dihydrothieno[3,2-*d*]pyrimidin-2(1H)-
607 ylidene)amino)azetidone-1-carboxylate (**5o**). Following the general procedure, using **2** (600 mg,
608 2.426 mmol), ethoxycarbonyl isothiocyanate (321 mg, 2.426 mmol, 0.29 mL), triethylamine
609 (736.5 mg, 7.278 mmol, 1.01 mL), *tert*-butyl 3-aminoazetidone-1-carboxylate (880 mg, 4.852
610 mmol, 0.80 mL), EDCI.HCl (558 mg, 2.911 mmol). After addition of water in the reaction
611 mixture, the obtained precipitate was filtered and purified by chromatography on alumina
612 (eluent: 99.5/0.5 DCM/MeOH to 95/05). The solid collected was a white solid (351 mg, 35%);
613 1H NMR (500 MHz, DMSO- d_6): δ 7.67 (d, 2H, CH_{ar} , $J = 8.1$ Hz), 7.35 (s, 1H, H-thiophene), 7.28
614 (d, 2H, CH_{ar} , $J = 7.9$ Hz), 6.88 (s, 2H, NH), 4.94 (qt, 1H, CH, $J = 7.4$ Hz), 4.33-4.32 (s, 2H, CH_2),
615 4.14 (t, 2H, CH_2 , $J = 8.1$ Hz), 2.34 (s, 3H, CH_3 -tolyl), 1.39 (s, 9H, $(CH_3)_3$); ^{13}C NMR (400 MHz,
616 DMSO- d_6): δ 158.7, 158.2, 156.0, 154.6, 150.7, 139.2, 130.2, 129.8, 125.9, 118.8, 111.5, 78.8,
617 55.0, 54.0, 53.4, 44.7, 28.1, 20.9; LC/MS: $t_r = 3.48$ min, $[M+H]^+ = 413.2$; HR-MS (ESI) $C_{21}H_{25}N_4O_3S$
618 calculated: 413.1642 $[M+H]^+$, found: 413.1644.

619

620 4.1.2.17. (*S*) *Tert*-butyl 3-((4-oxo-6-(*p*-tolyl)-3,4-dihydrothieno[3,2-*d*]pyrimidin-2(1H)-
621 ylidene)amino)-pyrrolidine-1-carboxylate (**5p**). Following the general procedure, using **2** (331
622 mg, 1.34 mmol), ethoxycarbonyl isothiocyanate (176 mg, 1.34 mmol, 0.16 mL), triethylamine
623 (407 mg, 4.02 mmol, 0.56 mL), (*S*)-*tert*-butyl 3-aminopyrrolidine-1-carboxylate (500 mg, 2.68
624 mmol, 0.47 mL), EDCI.HCl (282 mg, 1.47 mmol). After addition of water in the reaction mixture,
625 the obtained precipitate was filtered and purified by chromatography on alumina (eluent:
626 99/01 DCM/MeOH to 96/04). The solid collected was a white solid (282 mg, 49%); 1H NMR (400
627 MHz, DMSO- d_6): δ 10.67 (bs, 1H, NH), 7.68 (d, 2H, CH_{ar} , $J = 8.2$ Hz), 7.51 (s, 1H, H-thiophène),
628 7.27 (d, 2H, CH_{ar} , $J = 8.0$ Hz), 6.66 (bs, 1H, NH), 4.38-4.32 (m, 1H, CH), 3.57-3.54 (m, 1H, CH_2N),
629 3.34-3.33 (m, 2H, CH_2N), 3.20-3.16 (m, 1H, CH_2N), 2.34 (s, CH_3 , 3H), 2.18-2.08 (m, 1H, CH), 1.92-
630 1.84 (m, 1H, CH), 1.40-1.39 (m, 9H, $(CH_3)_3$); ^{13}C NMR (400 MHz, DMSO- d_6): δ 160.2, 157.7,
631 153.6, 153.0, 150.4, 139.1, 130.2, 129.8, 125.8, 119.7, 111.7, 78.5, 51.0 (d, $J = 124.8$ Hz), 50.4

632 (d, $J = 176.2$ Hz), 43.8 (d, $J = 20.2$ Hz), 30.6 (d, $J = 104.1$ Hz), 28.2, 20.9; LC/MS : $t_r = 1.87$ min,
633 $[M+H]^+ = 427.4$; HR-MS (ESI) $C_{22}H_{27}N_4O_3S$ calculated: 427.1806 $[M+H]^+$, found: 427.1798.

634

635 4.1.3. Synthesis of Compounds **6a** and **6b**

636 Compound **5o** (0.80 mmol) or **5p** (0.16 mmol) was dissolved in a 4/1 v/v solution of dioxane
637 and 37% aqueous HCl. The reaction mixture was stirred at room temperature for 1h. The
638 reaction was concentrated under reduce pressure. The solid was dissolved in ACN and water
639 and freeze-dried. An off-white powder was obtained (quantitative yield).

640

641 4.1.3.1. 2-(Azetidin-3-ylamino)-6-(*p*-tolyl)thieno[3,2-*d*]pyrimidin-4(3*H*)-one dihydrochloride
642 (**6a**). 1H NMR (500 MHz, DMSO- d_6): δ 9.59-9.58 (m, 1H, NH), 9.05 (br, 1H, NH), 8.10 (br, 1H, NH),
643 7.73-7.72 (m, 2H, CH_{ar}), 7.50 (s, 1H, H-thiophene), 7.30-7.31 (m, 2H, CH_{ar}), 5.28-5.22 (m, 1H,
644 CH), 4.42-4.49 (m, 2H, CH_2), 4.31-4.32 (m, 2H, CH_2), 2.34 (s, 3H, CH_3 -tolyl). ^{13}C NMR (400 MHz,
645 DMSO- d_6): δ 157.2, 156.3, 152.8, 151.4, 139.6, 130.0, 129.8, 125.9, 116.1, 111.6, 49.6, 47.1,
646 20.9. LC/MS : $t_r = 1.23$ min, $[M+H]^+ = 313.0$; HR-MS (ESI) $C_{16}H_{17}N_4OS$ calculated: 313.1118
647 $[M+H]^+$, found: 313.1116.

648

649 4.1.3.2. (S)-2-(pyrrolidin-3-ylamino)-6-(*p*-tolyl)thieno[3,2-*d*]pyrimidin-4(3*H*)-one
650 dihydrochloride (**6b**). 1H NMR (400 MHz, DMSO- d_6): δ 9.33-9.30 (m, 2H, NH), 7.68 (d, 2H, CH_{ar} ,
651 $J = 8.2$ Hz), 7.54 (s, 1H, H-thiophene), 7.29 (d, 2H, CH_{ar} , $J = 7.9$ Hz), 4.54-4.49 (m, 1H, CH), 3.50-
652 3.44 (m, 1H, CH_2), 3.38-3.31 (m, 1H, CH_2), 3.28-3.14 (m, 2H, CH_2), 2.34 (s, 3H, CH_3 -tolyl), 2.31-
653 2.24 (m, 1H, CH_2), 1.97-1.91 (m, 1H, CH_2); ^{13}C NMR (400 MHz, DMSO- d_6): δ 157.3, 157.1, 152.7,
654 151.0, 139.4, 130.0, 129.9, 125.9, 118.6, 112.1, 50.1, 49.4, 43.7, 30.2, 20.9; LC/MS : $t_r = 1.23$
655 min, $[M+H]^+ = 327.3$; HR-MS (ESI) $C_{17}H_{19}N_4OS$ calculated: 327.1274 $[M+H]^+$, found: 327.1283.

656

657 4.1.4. Synthesis of methyl 5-(*p*-tolyl)-3-((triphenylphosphoranylidene)amino)thiophene-
658 2-carboxylate **7**.

659 A mixture of methyl 3-amino-5-(*p*-tolyl)thiophene-2-carboxylate **2** (1eq., 2 g, 8.087 mmol) in
660 anhydrous ACN (60 mL) was stirred at 0°C. Then, PPh_3 (2 eq., 3.214 g, 12.13 mmol) and C_2Cl_6
661 (1.5 éq, 2.872 g, 12.13 mmol) were added. Then, Et_3N (3eq., 2.455 g, 24.26 mmol) was added
662 dropwise at 0°C. The color of the reaction mixture quickly turned to be orange. After stirring
663 for 2h30 at 0°C, the solvent was removed under reduced pressure and the residue was

664 recrystallized from EtOH to give compound **7** as an off-white powder (2.662 g, 65%); ¹H NMR
665 (500 MHz, DMSO-d₆): δ 7.86-7.84 (m, 6H, CH_{ar}), 7.67-7.58 (m, 9H, CH_{ar}), 7.22 (d, 2H, CH_{ar}, J =
666 8.2 Hz), 7.15 (d, 2H, CH_{ar}, J = 7.9 Hz), 6.35 (s, 1H, H-thiophene), 3.73 (s, 3H, CH₃O), 2.27 (s, 3H,
667 CH₃-tolyl); ¹³C NMR (500 MHz, DMSO-d₆): δ 162.5, 156.1, 145.2, 138.2, 132.3-132.2 (m), 130.3-
668 130.3 (m), 129.6, 128.9 (d, J = 11.9 Hz), 124.9, 120.0 (d, ³J = 9.4 Hz), 108.7 (d, J = 23.3 Hz), 50.5,
669 20.6; HR-MS (ESI) C₃₁H₂₇NO₂PS calculated: 508.1495 [M+H]⁺, found: 508.1497.

670

671 4.1.5. General Procedure for the Synthesis of 3-substituted thieno[3,2-*d*]pyrimidines
672 **10a-c.**

673 The appropriate isocyanate (1.5 to 3 eq.) under nitrogen atmosphere was added to a solution
674 of iminophosphorane **7** (1 eq.) in anhydrous DCM (0.500g/20mL). When the
675 iminophosphorane was consumed (HPLC monitored), the solvent was removed under reduced
676 pressure. The carbodiimide obtained was directly used without purification. *Tert*-butylamine
677 (1 to 3 eq.) was added to the solution of carbodiimide in anhydrous dichloromethane. After
678 complete consumption of the carbodiimide, the solvent was removed. The crude was
679 dissolved in anhydrous EtOH and several drops of EtONa (in EtOH) was added to the mixture.
680 The mixture was stirred at room temperature. After that, the solution was concentrated under
681 vacuum and the residual was purified by the appropriate purification method.

682

683 4.1.5.1. 2-(*Tert*-butylamino)-3-phenyl-6-(*p*-tolyl)thieno[3,2-*d*]pyrimidin-4(3*H*)-one (**10a**).
684 Following the general procedure, using **7** (1eq., 600 mg, 1.182 mmol), phenyl isocyanate (1.5
685 eq., 211 mg, 1.773 mmol, 193 μL). Then, *tert*-butylamine (1 eq., 56 mg, 0.7634 mmol, 81 μL)
686 was added to the carbodiimide (1 eq., 266 mg, 0.7634 mmol). The crude product was purified
687 by recrystallization in DCM/EtOH. A white powder was obtained (125 mg, 45%); ¹H NMR (500
688 MHz, DMSO-d₆): δ 7.73 (d, 2H, CH_{ar}, J = 8.1 Hz), 7.64-7.62 (m, 2H, CH_{ar}), 7.59-7.57 (m, 1H, CH_{ar}),
689 7.56 (s, 1H, H-thiophene), 7.43-7.42 (m, 2H, CH_{ar}), 7.29 (d, 2H, CH_{ar}, J = 8.0 Hz), 4.11 (bs, 1H,
690 NH), 2.35 (s, 3H, CH₃-tolyl), 1.33 (s, 9H, (CH₃)₃); ¹³C NMR (500 MHz, DMSO-d₆): δ 158.1, 157.2,
691 151.2, 150.9, 139.2, 134.8, 130.3, 130.1, 129.8, 129.7, 129.2, 125.8, 119.8, 115.5, 52.1, 28.4,
692 20.9; LC/MS: t_r = 2.31 min, [M+H]⁺ = 390.0; HR-MS (ESI) C₂₃H₂₄N₃OS calculated: 390.1640
693 [M+H]⁺, found: 390.1647.

694

695 4.1.5.2. 2-(*Tert*-butylamino)-3-ethyl-6-(*p*-tolyl)thieno[3,2-*d*]pyrimidin-4(3*H*)-one (**10b**).
696 Following the general procedure, using **7** (1eq., 500 mg, 0.985 mmol), isocyanatoethane (1.5

697 eq., 105 mg, 1.478 mmol, 117 μ L) and *tert*-butylamine (1 eq., 72 mg, 0.985 mmol, 104 μ L). The
698 crude product was purified by chromatography on silica gel (eluent: 90/10 Hexane/EtOAc to
699 100% EtOAc). An off-white solid was obtained (166 mg, 49%); ^1H NMR (500 MHz, DMSO- d_6): δ
700 7.68 (d, 2H, CH_{ar} , $J = 8.1$ Hz), 7.42 (s, 1H, H-thiophene), 7.27 (d, 2H, CH_{ar} , $J = 8.0$ Hz), 5.8(bs, 1H,
701 NH), 4.16 (q, 2H, CH_2CH_3 , $J = 7.0$ Hz), 2.34 (s, 3H, CH_3 -tolyl), 1.49 (s, 9H, $(\text{CH}_3)_3$), 1.15 (t, 3H,
702 CH_3CH_2 , $(\text{CH}_3)_3$, $J = 7.0$ Hz); ^{13}C NMR (500 MHz, DMSO- d_6): δ 157.6, 157.3, 151.0, 150.3, 139.0,
703 130.2, 129.7, 125.8, 119.6, 111.0, 52.2, 35.0, 28.7, 20.8, 12.5; LC/MS: $t_r = 2.32$ min, $[\text{M}+\text{H}]^+ =$
704 342.1; HR-MS (ESI) $\text{C}_{19}\text{H}_{24}\text{N}_3\text{OS}$ calculated: 342.1640 $[\text{M}+\text{H}]^+$, found: 342.1642.

705

706 4.1.5.3. 2-(*Tert*-butylamino)-3-isopropyl-6-(*p*-tolyl)thieno[3,2-*d*]pyrimidin-4(3*H*)-one (**10c**).
707 Following the general procedure, using **7** (1eq., 500 mg, 0.985 mmol), 2- isocyanatopropane (3
708 eq., 252 mg, 2.955 mmol, 290 μ L) and *tert*-butylamine (3 eq., 216 mg, 2.955 mmol, 312 μ L).
709 The crude product was purified by chromatography on silica gel (eluent: 90/10 Hexane/EtOAc
710 to 100% EtOAc) and with recrystallization in DCM/EtOH. Off-white crystals were obtained (207
711 mg, 59%); ^1H NMR (500 MHz, DMSO- d_6): δ 7.68 (d, 2H, CH_{ar} , $J = 8.1$ Hz), 7.43 (s, 1H, H-
712 thiophene), 7.27 (d, 2H, CH_{ar} , $J = 8.1$ Hz), 5.69 (bs, 1H, NH), 4.92-4.89 (m, 1H, CH), 2.33 (s, 3H,
713 CH_3 -tolyl), 1.50-1.48 (m, 15H, $(\text{CH}_2)_2$ et $(\text{CH}_3)_3$); ^{13}C NMR (500 MHz, DMSO- d_6): δ 158.4, 157.3,
714 151.6, 150.3, 139.0, 130.3, 129.8, 125.8, 119.5, 112.4, 52.4, 46.8, 28.8, 20.9, 19.8; LC/MS: $t_r =$
715 2.47 min, $[\text{M}+\text{H}]^+ = 356.2$; HR-MS (ESI) $\text{C}_{20}\text{H}_{26}\text{N}_3\text{OS}$ calculated: 356.1791 $[\text{M}+\text{H}]^+$, found :
716 356.1795.

717

718 4.2. Biology

719 All the in vitro biological evaluation assays, including blood-stage and hepatic antiplasmodial
720 evaluation,[14] MTT cell viability assay on HepG2 cells,[13] chromatographic hydrophobicity
721 index (CHI) Log $D_{7,4}$, microsomal stability and hERG inhibition assays[14] were performed as
722 previously reported.

723 4.2.1. Blood-Stage Antiplasmodial Evaluation

724 A K1 culture-adapted *P. falciparum* strain resistant to chloroquine, pyrimethamine, and
725 proguanil was used in an in vitro culture. It was maintained in a continuous culture, as
726 described previously by Trager and Jensen.[22] Cultures were maintained in fresh A+ human
727 erythrocytes at 2.5% hematocrit in a complete medium (RPMI 1640 with 25 mM HEPES, 25
728 mM NaHCO_3 , and 10% of A+ human serum) at 37°C under a reduced O_2 atmosphere (gas

729 mixture: 10% O₂, 5% CO₂, and 85% N₂). Parasitemia was maintained daily between 1 and 3%.
730 The *P. falciparum* drug susceptibility test was carried out by comparing quantities of DNA in
731 treated and control cultures of parasites in human erythrocytes, according to a SYBR Green I
732 fluorescence-based method[23] using a 96-well fluorescence plate reader. Compounds,
733 previously dissolved in DMSO (final concentration less than 0.5% v/v), were incubated in a total
734 assay volume of 200 µL (RPMI, 2% hematocrit and 0.4% parasitemia) for 72 h in a humidified
735 atmosphere (10% O₂ and 5% CO₂) at 37°C, in 96-well flat bottom plates. Duplicate assays were
736 performed for each sample. After incubation, plates were frozen at 20°C for 24 h. Then, the
737 frozen plates were thawed for 1 h at 37°C. A total of 15 µL of each sample was transferred to
738 96-well flat-bottom non-sterile black plates (Greiner Bio-One, Kremsmünster, Austria) already
739 containing 15 µL of the SYBR Green I lysis buffer (2X SYBR Green I, 20 mM Tris base pH 7.5, 20
740 mM EDTA, 0.008% w/v saponin, 0.08% w/v Triton X-100). Negative control treated by solvents
741 (DMSO or H₂O) and positive controls (chloroquine) were added to each set of experiments.
742 Plates were incubated for 15 min at 37°C and then read on a TECAN Infinite F-200
743 spectrophotometer with excitation and emission wavelengths at 485 and 535 nm, respectively.
744 The concentrations of compounds required to induce a 50% decrease in parasite growth (EC₅₀
745 K1) were calculated from three independent experiments.

746 4.2.2. Cytotoxicity Evaluation

747 The HepG2 cell line was maintained at 37°C, 5% CO₂, at 90% humidity in MEM supplemented
748 with 10% fetal bovine serum, 1% L-glutamine (200 mM), and penicillin (100
749 U/mL)/streptomycin (100 µg/mL) (complete RPMI medium). The cytotoxicity of the tested
750 molecules on the HepG2 (hepatocarcinoma cell line purchased from ATCC, ref HB-8065) cell
751 line was assessed according to the method of Mosmann[24] with slight modifications. Briefly,
752 5.103 cells in 100 µL of complete medium were inoculated into each well of 96-well plates and
753 incubated at 37°C in humidified 5% CO₂. After 24 h incubation, 100 µL of medium with various
754 product concentrations dissolved in DMSO (final concentration less than 0.5% v/v) were added
755 and the plates were incubated for 72 h at 37°C. Triplicate assays were performed for each
756 sample. Each plate was then microscopically examined for possible precipitate formation
757 before the medium was aspirated from the wells. Next, 100 µL of MTT (3-(4,5-dimethyl-2-
758 thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) solution (0.5 mg/mL in medium without FBS)
759 was added to each well. Cells were incubated for 2 h at 37°C. After this time, the MTT solution
760 was removed and DMSO (100 µL) was added to dissolve the resulting blue formazan crystals.
761 Plates were shaken vigorously (700 rpm) for 10 min. The absorbance was measured at 570 nm
762 with 630 nm as the reference wavelength using a BIO-TEK ELx808 Absorbance Microplate

763 Reader (LabX, Midland, ON, Canada). DMSO was used as blank and doxorubicin (purchased
764 from Sigma Aldrich) as positive control. Cell viability was calculated as a percentage of control
765 (cells incubated without compounds). The 50% cytotoxic concentration (CC₅₀) was determined
766 from the dose–response curve, using TableCurve software 2D v.5.0. CC₅₀ values to represent
767 the mean value calculated from three independent experiments.

768 4.2.3. Hepatic-Stage Antiplasmodial Evaluation

769 4.2.2.1. Parasite Strains and Sporozoite Isolation

770 *P. berghei* sporozoites constitutively expressing green fluorescent protein (*PbGFP*, ANKA
771 strain)[25] were obtained by the dissection of salivary glands from infected *Anopheles*
772 *stephensi* mosquitoes bred and infected in the insectary facilities of UMR-S 1135 (CIMI, Paris,
773 France). Infected salivary glands were removed by hand dissection, crushed in a potter, and
774 filtered through a 40 µm filter for sporozoite isolation (Cell Strainer, BD BioSciences, San Jose,
775 CA, USA). The sporozoites were counted using a disposable plastic microscope slide (KOVA).

776 4.2.2.2. Primary Hepatocyte Culture

777 Primary simian hepatocytes were isolated from liver segments collected from healthy *Macaca*
778 *fascicularis* from the facilities of the Centre d'Energie Atomique (CEA) (Fontenay-aux-Roses,
779 France). All hepatocytes were obtained using collagenase perfusion, as previously
780 described[26], and were immediately cryopreserved. One day before infection, the
781 cryopreserved hepatocytes were thawed at 37°C and were seeded into collagen-coated (5
782 µg/cm² rat tail collagen I, Invitrogen, Carlsbad, CA, USA) 96-well plate, at a density of 80,000
783 cells per well. They were cultured at 37°C in 5% CO₂ in William's E medium (Gibco, Life
784 Technologies, Saint Aubin, France) supplemented with 10% of Fetal Bovine Serum FCIII, 5 x
785 10⁻⁵ M hydrocortisone hemisuccinate (Serb Laboratories, Paris, France), 5 µg per ml bovine
786 insulin (Sigma Aldrich, St. Louis, MO, USA), 2 mM L-glutamine, and 0.02 U per ml-0.02 µg per
787 ml penicillinstreptomycin (Life Technologies) until infection with sporozoites.

788 4.2.2.3. *In Vitro* Infection and Drug Assays

789 Sporozoites of *P. berghei* were re-suspended in the above complete medium used for the
790 hepatocytes culture. Simian hepatocytes were inoculated in 50 µL of complete media with
791 20,000 *P. berghei*-sporozoites/well in 96-well plates. The infected culture plates were
792 centrifuged for 6 min at 900x g to allow fast parasite sedimentation onto the target cells and
793 were further incubated with the serial dilution of drugs that were prepared in advance. After
794 3 h of incubation, cultures were washed and further incubated in a fresh medium containing

795 the appropriate drug concentration, which were changed every 24 h during the study period.
796 Cultured hepatocytes were fixed using 4% paraformaldehyde (PFA) for 15 min at room
797 temperature. Host cell and parasite nuclei were labeled with 4',6-diamidino-2-phenylindole
798 (DAPI). Upon fixation and immunostaining, cell culture plates were analysed to determine the
799 number and size of the parasites using a Cell Insight High Content Screening platform equipped
800 with the Studio HCS software (Thermo Fisher Scientific, Waltham, MA, USA). The parasite size
801 reduction was calculated on the average object area using the total surface area of each
802 selected object (μm^2). To assess the cell toxicity of drugs for hepatic cultures, fixed plates were
803 further scanned for the DAPI signal representing host nuclei. The analysis was based on
804 counting of total cell nuclei. GraphPad Prism 7 statistical software (GraphPad. Software, San
805 Diego, CA, USA) was used for data analysis and graphing. All values were expressed as means
806 and standard deviations (SD).

807

808

809 4.3. *Physicochemical Properties*

810 4.3.1. Determination of Solubility in PBS

811 1 mg of compound was weighted into an Eppendorf and 1 mL of PBS was added. The mixture
812 was sonicated for 10 min and then stirred at 25°C overnight. The mixture was centrifuged for
813 10 min at 3000 rpm. The supernatant was recovered and filtered. 10 μL were injected in
814 analytical HPLC. The area under the curve corresponding to the product was measured at 214
815 nm and compared to the calibration curves obtained after injection of a range of the product
816 previously solubilized in methanol (concentrations 50, 125, 250, 400, 500 μM). Calibration
817 curves were linear with $R^2 > 0.99$.

818 4.3.2. Chromatographic Hydrophobicity Index (CHI) $\text{Log } D_{7,4}$

819 The determination of Chromatographic Hydrophobicity Index (CHI)[27] at neutral pH was
820 realized by retention time measurements using a 1290 Agilent chromatographic system
821 (Agilent Technologies, Santa Clara, California, USA) equipped with a PDA detector 1260
822 operating at 220, 240, 254, 290 and 350 nm for all compounds using a Ultra C18 column (5 μm ,
823 3 x 50 mm) from Restek (Lisses, France). Before measurements, compounds were dissolved
824 (100 μM) in methanol. In the used HPLC method, the flow rate was 0.3 mL/min, the
825 temperature was kept constant at 30°C. The mobile phase A was made of 50 mM ammonium
826 acetate aqueous solution, and the mobile phase B was ACN. A HPLC gradient method was

827 applied, with 0 to 0.2 min: 0% B solvent; 0.2 to 3.5 min: 0 to 100% B solvent; 3.5 to 4.0 min:
828 100% B solvent; post run: 2 min. Standard compounds were theophylline, 5-Phenyltetrazole,
829 benzimidazole, acetophenone, indole, propiophenone, butyrophenone, valerophenone, with
830 $R^2 > 0.999$. The Chromatographic Hydrophobicity data expressed as CHI LogD was calculated as
831 previously described)[28].

832 4.3.3. Permeability Determination by PAMPA-GIT Assay

833 The Parallel Artificial Membrane Permeability (PAMPA)-GIT experiments were conducted
834 using the Pampa Explorer Kit (Pion Inc) according to manufacturer's protocol. Usually, the
835 studied compound is dissolved in DMSO at 20 mM. Considering that the studied molecule was
836 poorly soluble in DMSO, a stock solution at 10 mM was realized, and was then diluted to 50
837 μM in Prisma HT buffer pH 7.4, 6.0 or 5.0 (Pion Inc). 200 μL of these solutions ($n = 4$) were
838 added to the donor plate (P/N 110243). GIT-0 Lipid (5 μL , P/N 110669) was used to coat the
839 membrane filter of the acceptor plate (P/N 110243). The acceptor Sink Buffer (200 μL , P/N
840 110139) was added to each well of the acceptor plate. The sandwich was incubated at room
841 temperature for 4h, without stirring. After the incubation the UV-visible spectra were
842 measured with the microplate reader (Tecan infinite M200), and the permeability value (P_e)
843 was calculated by the PAMPA Explorer software v.3.7 (pION) for each compound. Antipyrine
844 and ketoprofen were used as references.

845 4.3.4. hERG Inhibition Assay

846 hERG channel binding of the compound is determined with the PredictorTM hERG
847 Fluorescence Polarization Assay, that permits hERG channel biochemical binding studies in the
848 absence of radioligands. The assay is based on the principle of fluorescence polarization, where
849 a red-shifted fluorescent tracer displays a high polarization when bound to the hERG channel
850 and a low polarization when displaced by compounds that bind to the channel.

851 Materials and Methods: hERG channel binding was determined with the PredictorTM hERG
852 Fluorescence Polarization Assay (PV5665 ThermoFischer). Briefly, reagents were thawed, and
853 were mixed by pipetting 20x with PredictorTM hERG membranes. The fluorescent tracer was
854 diluted at 4 nM in the PredictorTM hERG buffer. The tested compound was dissolved in DMSO
855 at 10 mM and was then diluted from 0.4 μM to 0.04 nM in the PredictorTM hERG buffer. The
856 assay was performed in a 96-well Greiner microplate (675093 Dutscher). 25 μL of each
857 concentration of M1 were dispensed into the plate. Then, 50 μL of the PredictorTM hERG
858 membranes and 25 μL of the fluorescent tracer 4 nM were added. The plate was incubated at
859 room temperature for 4 hours. The fluorescence polarization measurements were made using

860 a Synergy 2 microplate reader (Biotek Instrument, Colmar, France). Both parallel and
861 perpendicular fluorescence were measured using 530/25 nm excitation and 590/35 nm
862 emission filters with a 570 nm dichroic mirror. The gain was fixed at 110. A known hERG
863 channel blocker (E-4031), provided by the kit, was assayed as positive reference. E-4031,
864 LP0373 and LP0374 were tested at final concentrations ranging from 0.01 nM to 100 μ M. IC50
865 values were determined graphically by plotting the % inhibition versus the logarithm of 9
866 concentrations of each compound in the assay solution using the GraphPad Prism software
867 (version 6.01, GraphPad Software, La Jolla, CA, USA).

868 4.4. *Microsomal Stability*

869 The tested products and propranolol, used as a reference, were incubated in duplicate
870 (reaction mixture volume of 0.5 mL) with female mouse microsomes (CD-1, 20 mg mL⁻¹; BD
871 Gentest) at 37 °C in a 50 mM phosphate buffer, pH 7.4, in the presence of MgCl₂ (5 mM), NADP
872 (1 mM), glucose-6-phosphate dehydrogenase (G6PD) (0.4U per mL), and glucose-6-phosphate
873 (5 mM). For the estimation of the intrinsic clearance, 50 μ L aliquots were collected at 0, 5, 10,
874 20, 30, and 40 min and the reaction was stopped with 4 volumes of acetonitrile (ACN)
875 containing the internal standard. After centrifugation at 12000 rpm for 10 min at 4 °C, the
876 supernatants are kept at 4°C for immediate analysis. Controls (time zero and final time point)
877 in triplicate were prepared by the incubation of the internal standard with microsomes
878 denatured by acetonitrile. The calculation of the half-life ($t_{1/2}$) of each compound in the
879 presence of microsomes was carried out according to the equation $t_{1/2} = (\ln 2)/k$, where k is the
880 first-order degradation constant (the slope of the logarithm of the compound concentration
881 versus incubation time). The intrinsic clearance in vitro (Cl_{int} , expressed in mL.min⁻¹.mg) was
882 calculated according to the equation $Cl_{int} = (\text{dose}/AUC_{\infty})/[\text{microsomes}]$, where dose is the
883 initial concentration of the product in the sample, AUC_{∞} is the area under the concentration–
884 time curve extrapolated to infinity, and [microsomes] is the microsome concentration
885 expressed in mg.mL⁻¹.

886 5. **Acknowledgements**

887 This work was financially supported by the Agence Nationale de la Recherche (ANR Plasmodrug
888 18-CE18-0009-01) and the Fondation pour la Recherche Médicale (FRM Palukill
889 DMC20181039565). We want to thank M Pierre Sanchez (Institut des Biomolécules Max
890 Mousseron, Montpellier) for his help with MS analyses and Ms Catherine Piveteau (Institut
891 Pasteur de Lille) for performing microsomal stability studies.

- 893 [1] World Health Organization, World malaria report 2022, (n.d.).
 894 <https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2022>
 895 (accessed June 7, 2022).
- 896 [2] R.O. Makanjuola, A.W. Taylor-Robinson, Improving Accuracy of Malaria Diagnosis in Underserved
 897 Rural and Remote Endemic Areas of Sub-Saharan Africa: A Call to Develop Multiplexing Rapid
 898 Diagnostic Tests, *Scientifica* (Cairo). 2020 (2020) 3901409.
 899 <https://doi.org/10.1155/2020/3901409>.
- 900 [3] T.E. Nkya, U. Fillinger, O.P. Sangoro, R. Marubu, E. Chanda, C.M. Mutero, Six decades of malaria
 901 vector control in southern Africa: a review of the entomological evidence-base, *Malar. J.* 21
 902 (2022) 279. <https://doi.org/10.1186/s12936-022-04292-6>.
- 903 [4] A.O. Adeyemo, A.T. Aborode, M.A. Bello, A.F. Obianuju, M.M. Hasan, D.O. Kehinde, M.S. Hossain,
 904 M. Bardhan, J.O. Imisioluwa, A.A. Akintola, Malaria vaccine: The lasting solution to malaria
 905 burden in Africa, *Ann. Med. Surg. (Lond)*. 79 (2022) 104031.
 906 <https://doi.org/10.1016/j.amsu.2022.104031>.
- 907 [5] H. Tripathi, P. Bhalerao, S. Singh, H. Arya, B.S. Alotaibi, S. Rashid, M.R. Hasan, T.K. Bhatt, Malaria
 908 therapeutics: are we close enough?, *Parasites & Vectors*. 16 (2023) 130.
 909 <https://doi.org/10.1186/s13071-023-05755-8>.
- 910 [6] B. Hanboonkunupakarn, J. Tarning, S. Pukrittayakamee, K. Chotivanich, Artemisinin resistance
 911 and malaria elimination: Where are we now?, *Front. Pharmacol.* 13 (2022) 876282.
 912 <https://doi.org/10.3389/fphar.2022.876282>.
- 913 [7] C. Wongsrichanalai, C.H. Sibley, Fighting drug-resistant *Plasmodium falciparum*: the challenge of
 914 artemisinin resistance, *Clinical Microbiology and Infection*. 19 (2013) 908–916.
 915 <https://doi.org/10.1111/1469-0691.12316>.
- 916 [8] H. Bosson-Vanga, N. Primas, J.-F. Franetich, C. Lavazec, L. Gomez, K. Ashraf, M. Tefit, V. Soulard,
 917 N. Dereuddre-Bosquet, R. Le Grand, M. Donnette, R. Mustière, N. Amanzougaghene, S. Tajeri, P.
 918 Suzanne, A. Malzert-Fréon, S. Rault, P. Vanelle, S. Hutter, A. Cohen, G. Snounou, P. Roques, N.
 919 Azas, P. Lagardère, V. Lisowski, N. Masurier, M. Nguyen, L. Paloque, F. Benoit-Vical, P. Verhaeghe,
 920 D. Mazier, A New Thienopyrimidinone Chemotype Shows Multistage Activity against *Plasmodium*
 921 *falciparum*, Including Artemisinin-Resistant Parasites, *Microbiol. Spectr.* 9 (2021) e00274-21.
 922 <https://doi.org/10.1128/Spectrum.00274-21>.
- 923 [9] A. Cohen, P. Suzanne, J.-C. Lancelot, P. Verhaeghe, A. Lesnard, L. Basmaciyan, S. Hutter, M. Laget,
 924 A. Dumètre, L. Paloque, E. Deharo, M.D. Crozet, P. Rathelot, P. Dallemagne, A. Lorthiois, C.H.
 925 Sibley, P. Vanelle, A. Valentin, D. Mazier, S. Rault, N. Azas, Discovery of new thienopyrimidinone
 926 derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of
 927 *Plasmodium*, *Eur. J. Med. Chem.* 95 (2015) 16–28.
 928 <https://doi.org/10.1016/j.ejmech.2015.03.011>.
- 929 [10] P. Lagardère, R. Mustière, N. Amanzougaghene, S. Hutter, J.-F. Franetich, N. Azas, P. Vanelle, P.
 930 Verhaeghe, N. Primas, D. Mazier, N. Masurier, V. Lisowski, 4-Substituted Thieno[3,2-
 931 d]pyrimidines as Dual-Stage Antiplasmodial Derivatives, *Pharmaceuticals*. 15 (2022) 820.
 932 <https://doi.org/10.3390/ph15070820>.
- 933 [11] P. Lagardère, C. Fersing, N. Masurier, V. Lisowski, Thienopyrimidine: A Promising Scaffold to
 934 Access Anti-Infective Agents, *Pharmaceuticals*. 15 (2022) 35.
 935 <https://doi.org/10.3390/ph15010035>.
- 936 [12] R. Mustière, P. Lagardère, S. Hutter, C. Deraeve, F. Schwalen, D. Amrane, N. Masurier, N. Azas, V.
 937 Lisowski, P. Verhaeghe, D. Mazier, P. Vanelle, N. Primas, Pd-catalyzed C–C and C–N cross-coupling
 938 reactions in 2-aminothieno[3,2-d]pyrimidin-4(3H)-one series for antiplasmodial
 939 pharmacomodulation, *RSC Adv.* 12 (2022) 20004–20021. <https://doi.org/10.1039/D2RA01687G>.
- 940 [13] R. Mustière, P. Lagardère, S. Hutter, V. Dell’Orco, N. Amanzougaghene, S. Tajeri, J.-F. Franetich,
 941 S. Corvaisier, M. Since, A. Malzert-Fréon, N. Masurier, V. Lisowski, P. Verhaeghe, D. Mazier, N.

942 Azas, P. Vanelle, N. Primas, Synthesis of antiplasmodial 2-aminothieno[3,2-d]pyrimidin-4(3H)-
 943 one analogues using the scaffold hopping strategy, *Eur. J. Med. Chem.* 241 (2022) 114619.
 944 <https://doi.org/10.1016/j.ejmech.2022.114619>.

945 [14] P. Lagardère, R. Mustière, N. Amanzougaghene, S. Hutter, M. Casanova, J.-F. Franetich, S. Tajeri,
 946 A. Malzert-Fréon, S. Corvaisier, N. Azas, P. Vanelle, P. Verhaeghe, N. Primas, D. Mazier, N.
 947 Masurier, V. Lisowski, New antiplasmodial 4-amino-thieno[3,2-d]pyrimidines with improved
 948 intestinal permeability and microsomal stability, *Eur. J. Med. Chem.* 249 (2023) 115115.
 949 <https://doi.org/10.1016/j.ejmech.2023.115115>.

950 [15] D. González Cabrera, F. Douelle, C. Le Manach, Z. Han, T. Paquet, D. Taylor, M. Njoroge, N.
 951 Lawrence, L. Wiesner, D. Waterson, M.J. Witty, S. Wittlin, L.J. Street, K. Chibale, Structure–
 952 Activity Relationship Studies of Orally Active Antimalarial 2,4-Diamino-thienopyrimidines, *J. Med.*
 953 *Chem.* 58 (2015) 7572–7579. <https://doi.org/10.1021/acs.jmedchem.5b01156>.

954 [16] D. González Cabrera, C. Le Manach, F. Douelle, Y. Younis, T.-S. Feng, T. Paquet, A.T. Nchinda, L.J.
 955 Street, D. Taylor, C. de Kock, L. Wiesner, S. Duffy, K.L. White, K.M. Zabiulla, Y. Sambandan, S.
 956 Bashyam, D. Waterson, M.J. Witty, S.A. Charman, V.M. Avery, S. Wittlin, K. Chibale, 2,4-
 957 Diaminothienopyrimidines as Orally Active Antimalarial Agents, *J. Med. Chem.* 57 (2014) 1014–
 958 1022. <https://doi.org/10.1021/jm401760c>.

959 [17] S. Markey, Pathways of Drugs Metabolism., in: *Principles of Clinical Pharmacology - 3rd Edition*,
 960 2012: pp. 153–172.

961 [18] F.P. Guengerich, Kinetic Deuterium Isotope Effects in Cytochrome P450 Reactions, *Methods*
 962 *Enzymol.* 596 (2017) 217–238. <https://doi.org/10.1016/bs.mie.2017.06.036>.

963 [19] C. Schmidt, First deuterated drug approved, *Nature Biotechnology.* 35 (2017) 493–494.
 964 <https://doi.org/10.1038/nbt0617-493>.

965 [20] ClogD values were calculated with ACD/ChemSketch v6.00, Advanced Chemistry Development,
 966 Inc., Toronto, Canada, 2002. www.acdlabs.com, (n.d.).

967 [21] A.R. MacKenzie, A.P. Marchington, D.S. Middleton, S.D. Newman, B.C. Jones, Structure–Activity
 968 Relationships of 1-Alkyl-5-(3,4-dichlorophenyl)-5-{2-[(3-substituted)-1-azetidiny]ethyl}-2-
 969 piperidones. 1. Selective Antagonists of the Neurokinin-2 Receptor, *J. Med. Chem.* 45 (2002)
 970 5365–5377. <https://doi.org/10.1021/jm0209331>.

971 [22] W. Trager, J.B. Jensen, Human malaria parasites in continuous culture, *Science.* 193 (1976) 673–
 972 675. <https://doi.org/10.1126/science.781840>.

973 [23] W.A. Guiguemde, A.A. Shelat, D. Bouck, S. Duffy, G.J. Crowther, P.H. Davis, D.C. Smithson, M.
 974 Connelly, J. Clark, F. Zhu, M.B. Jiménez-Díaz, M.S. Martinez, E.B. Wilson, A.K. Tripathi, J. Gut, E.R.
 975 Sharlow, I. Bathurst, F.E. Mazouni, J.W. Fowble, I. Forquer, P.L. McGinley, S. Castro, I. Angulo-
 976 Barturen, S. Ferrer, P.J. Rosenthal, J.L. DeRisi, D.J. Sullivan, J.S. Lazo, D.S. Roos, M.K. Riscoe, M.A.
 977 Phillips, P.K. Rathod, W.C. Van Voorhis, V.M. Avery, R.K. Guy, Chemical genetics of *Plasmodium*
 978 *falciparum*, *Nature.* 465 (2010) 311–315. <https://doi.org/10.1038/nature09099>.

979 [24] T. Mosmann, Rapid colorimetric assay for cellular growth and survival: Application to
 980 proliferation and cytotoxicity assays, *Journal of Immunological Methods.* 65 (1983) 55–63.
 981 [https://doi.org/10.1016/0022-1759\(83\)90303-4](https://doi.org/10.1016/0022-1759(83)90303-4).

982 [25] C.J. Janse, B. Franke-Fayard, G.R. Mair, J. Ramesar, C. Thiel, S. Engelmann, K. Matuschewski, G.J.
 983 van Gemert, R.W. Sauerwein, A.P. Waters, High efficiency transfection of *Plasmodium berghei*
 984 facilitates novel selection procedures, *Molecular and Biochemical Parasitology.* 145 (2006) 60–
 985 70. <https://doi.org/10.1016/j.molbiopara.2005.09.007>.

986 [26] O. Silvie, E. Rubinstein, J.-F. Franetich, M. Prenant, E. Belnoue, L. Rénia, L. Hannoun, W. Eling, S.
 987 Levy, C. Boucheix, D. Mazier, Hepatocyte CD81 is required for *Plasmodium falciparum* and
 988 *Plasmodium yoelii* sporozoite infectivity, *Nat Med.* 9 (2003) 93–96.
 989 <https://doi.org/10.1038/nm808>.

990 [27] K. Valkó, C. Bevan, D. Reynolds, Chromatographic Hydrophobicity Index by Fast-Gradient RP-
 991 HPLC: A High-Throughput Alternative to log P/log D, *Anal Chem.* 69 (1997) 2022–2029.
 992 <https://doi.org/10.1021/ac961242d>.


993 [28] K. Valkó, Application of high-performance liquid chromatography based measurements of
994 lipophilicity to model biological distribution, J Chromatogr A. 1037 (2004) 299–310.
995 <https://doi.org/10.1016/j.chroma.2003.10.084>.
996

997

Preprint not peer reviewed

998

Graphical Abstract



- ✓ Active against *P. falciparum* erythrocytic stage
- ✓ Active against *P. berghei* hepatic stage
- ✗ Not permeable (PAMPA-GIT, pH 5.0 and 7.4)
- ✗ Weak microsomal stability

- ✓ Active against *Pf* erythrocytic stage
- ✓ Active against *Pb* hepatic stage
- ✓ Permeable (PAMPA-GIT, pH 5.0 and 7.4)
- ✓ Improved microsomal stability

999

1000

Highlights

- A series of 19 new thienopyrimidones was synthesized.
- 6 compounds showed an $EC_{50} \leq 1.5 \mu M$ against the blood stage of *P. falciparum* K1.
- 5 compounds showed higher activity against the hepatic stage of *P. berghei* than Gamhepathiopine.
- 3 compounds exhibited improved microsomal stability compared to Gamhepathiopine.
- Compound **5g** showed the better compromise between activity, cytotoxicity and microsomal stability.

1009

1010

1011

1012

1013

1014

1015

1016

1017